{
    "K143467.txt": {
        "applicant": "TaiDoc Technology Corporation",
        "conclusion": "The submitted information in this premarket notification is complete and supports a substantial equivalence decision.",
        "classification": "Class II",
        "panel": "Clinical Chemistry (75)",
        "measurand": "Capillary whole blood glucose from the fingertip, palm, forearm, and upper arm",
        "submission_number": "k143467",
        "intended_use": "The FORA GD43 Blood Glucose Monitoring System is intended to be used for the quantitative measurement of glucose (sugar) in fresh capillary whole blood from the fingertip and alternative sites (palm, forearm and upper arm). This blood glucose monitoring system is intended to be used by a single person and should not be shared. Alternative site testing (AST) should only be done during steady-state times (when glucose is not changing rapidly). The FORA GD43 Blood Glucose Monitoring System is intended for self-testing outside the body (in vitro diagnostic use) by people with diabetes at home as an aid to monitor the effectiveness of diabetes control. This system should not be used for the diagnosis of or screening for diabetes, nor for use on neonates.",
        "regulation_section": "21 CFR 862.1345, Glucose test system",
        "product_code": "NBW, System, Test, Blood Glucose, Over the Counter; LFR, Glucose Dehydrogenase, Glucose",
        "comparison_with_predicate": "Similarities: Indications for Use/Intended Use, Enzyme, Test Method, Measuring Range, Reaction time, Memory Capacity, Dimensions, Weight. Differences: Sample type, Electrode, Sample volume, Hematocrit range, Test Strip stability, Operating conditions."
    },
    "K171742.txt": {
        "applicant": "Siemens Healthcare Diagnostics Products GmbH",
        "conclusion": "The submitted information in this premarket notification is complete and supports a substantial equivalence decision.",
        "classification": "Class II, test systems",
        "panel": "Immunology (82)",
        "measurand": "Kappa (\u03ba) Free Light Chain (FLC), Lambda (\u03bb) Free Light Chain (FLC)",
        "submission_number": "K171742",
        "intended_use": "In-vitro diagnostic reagents for the quantitative determination of free light chains (FLC), type kappa or type lambda in human serum and EDTA-plasma by means of particle-enhanced immunonephelometry using the BN Systems. FLC measurements are used as an aid in the diagnosis of multiple myeloma (MM) and amyloidosis (AL).",
        "regulation_section": "21 CFR \u00a7 866.5550 \u2013 Immunoglobulin (light chain specific) immunological test system, 21 CFR \u00a7 862.1660 \u2013 Quality Control Material (assayed and unassayed)",
        "product_code": "DFH, Kappa, antigen, antiserum, control; DEH, Lambda, antigen, antiserum, control",
        "comparison_with_predicate": "Kappa and Lambda Reagents: Similarities: Analyte: Kappa: Kappa FLC, Lambda: Lambda FLC, Measurement: Quantitative, Detection Method: Nephelometric. Differences: Indication for use: In-vitro diagnostic reagents for the quantitative determination of free light chains (FLC), type kappa or type lambda, in human serum and EDTA plasma by means of particle-enhanced immunonephelometry using the BN Systems. FLC measurements are used as an aid in the diagnosis of multiple myeloma (MM) and amyloidosis (AL)."
    },
    "K170491.txt": {
        "applicant": "Quidel Corporation",
        "conclusion": "The submitted information in this premarket notification is complete and supports a substantial equivalence decision.",
        "classification": "II",
        "panel": "Microbiology (83)",
        "measurand": "tcdA gene of toxigenic Clostridium difficile",
        "submission_number": "K170491",
        "intended_use": "The Solana C. difficile assay is an in vitro diagnostic test for the direct, qualitative detection of the Clostridium difficile Toxin A gene (tcdA) in unformed stool specimens of patients suspected of having Clostridium difficile infection (CDI). The Solana C. difficile assay is intended for use as an aid in diagnosis of CDI. The assay utilizes helicase\u2010dependent amplification (HDA) for the amplification of a highly conserved fragment of the Toxin A gene sequence. The Solana C. difficile Assay is intended for use only with the Solana instrument.",
        "regulation_section": "21 CFR 866.3130, Clostridium difficile toxin gene amplification assay",
        "product_code": "OZN",
        "comparison_with_predicate": "The Solana C. difficile Assay and the Portrait Toxigenic C. difficile Assay both detect toxigenic Clostridium difficile, but the Solana assay targets the Toxin A gene (tcdA) and uses the Solana instrument, while the Portrait assay targets the Toxin B gene (tcdB) and uses the Portrait Analyzer."
    },
    "K161220.txt": {
        "applicant": "Luminex Corporation",
        "conclusion": "The submitted information in this premarket notification is complete and supports a substantial equivalence decision.",
        "classification": "Class II",
        "panel": "Microbiology (83)",
        "measurand": "Influenza A RNA: Matrix gene, Influenza B RNA: Matrix gene, Respiratory Syncytial Virus (RSV) RNA: Fusion gene of RSV A and RSV B",
        "submission_number": "K161220",
        "intended_use": "The ARIES\u00ae Flu A/B & RSV Assay is a polymerase chain reaction (PCR) based qualitative in vitro diagnostic test for the direct detection and differentiation of influenza A virus, influenza B virus, and respiratory syncytial virus (RSV) nucleic acid in nasopharyngeal swab (NPS) specimens from patients with signs and symptoms of respiratory tract infection in conjunction with clinical and laboratory findings. The test is intended for use as an aid in the differential diagnosis of Influenza A, Influenza B, and RSV in humans and is not intended to detect Influenza C.",
        "regulation_section": "21 CFR 866.3980, Respiratory viral panel multiplex nucleic acid assay",
        "product_code": "OCC, OOI, OZE",
        "comparison_with_predicate": "Similarities: Regulation - 866.3980, Product Code - OCC, OOI, Device Classification - II, Intended Use - The ARIES Flu A/B & RSV Assay is a polymerase chain reaction (PCR) based qualitative in vitro diagnostic test for the direct detection and differentiation of influenza A virus, influenza B virus, and respiratory syncytial virus (RSV) nucleic acid in nasopharyngeal swab (NPS) specimens from patients with signs and symptoms of respiratory tract infection in conjunction with clinical and laboratory findings. The test is intended for use as an aid in the differential diagnosis of Influenza A, Influenza B, and RSV in humans and is not intended to detect Influenza C."
    },
    "K172913.txt": {
        "applicant": "Roche Molecular Systems, Inc.",
        "conclusion": "The submitted information in this premarket notification is complete and supports a substantial equivalence decision.",
        "classification": "Class II",
        "panel": "Hematology (81)",
        "measurand": "Factor II and Factor V",
        "submission_number": "K172913",
        "intended_use": "The cobas\u00ae Factor II and Factor V Test is an in vitro diagnostic device that uses real-time PCR for the detection and genotyping of the Factor II (Prothrombin) G20210A mutation and the Factor V Leiden G1691A mutation in genomic DNA obtained from K2EDTA whole blood specimens as an aid in diagnosis of patients with suspected thrombophilia.",
        "regulation_section": "21 CFR 84.7280; Factor V Leiden DNA Mutation Detection Systems",
        "product_code": "NPR; Test, Factor II G20210A Mutations, Genomic DNA PCR, Factor V Leiden DNA Mutation Detection Systems NPQ; Test, Factor V Leiden Mutations, Genomics DNA PCR, Factor V Leiden DNA Mutation Detection Systems",
        "comparison_with_predicate": "Similarities: Intended Use, Type of Test, Target of Detection, Indication for Use, Intended User, Specimen Type. Differences: Technological Detection Principles, Oligonucleotide probes and primers, Detection Chemistry, Analytical Sensitivity, Instrument, Controls, Reference method."
    },
    "K160082.txt": {
        "applicant": "Puritan Medical Products, LLC",
        "conclusion": "The submitted information in this premarket notification is complete and supports a substantial equivalence decision.",
        "classification": "Class I",
        "panel": "83- Microbiology",
        "measurand": "Not applicable.",
        "submission_number": "K160082",
        "intended_use": "The Puritan Opti-Tranz Cary-Blair Collection and Transport System is intended for use in the collection and transport of clinical fecal and rectal swab specimens to preserve the viability of enteric bacteria during transport from the collection site to the testing laboratory for bacteriological examination and culture.",
        "regulation_section": "866.2390; Transport Culture Medium",
        "product_code": "JSM; Culture Media, Non-Propagating Transport",
        "comparison_with_predicate": "Similarities: Intended Use, Specimen Storage, Tube, Medium Volume, Single Use Device, Packaging, Swab, Medium Formulation. Differences: Organisms Tested, pH, Shelf life."
    },
    "K180886.txt": {
        "applicant": "Liofilchem s.r.l.",
        "conclusion": "The submitted information in this premarket notification is complete and supports a substantial equivalence decision.",
        "classification": "II",
        "panel": "83 \u2013 Microbiology",
        "measurand": "Delafloxacin 0.002-32 \u03bcg/mL",
        "submission_number": "K180886",
        "intended_use": "The Liofilchem\u00ae MIC Test Strip (MTS) is a quantitative method intended for the in vitro determination of antimicrobial susceptibility of bacteria.",
        "regulation_section": "866.1640 Antimicrobial Susceptibility Test Powder",
        "product_code": "JWY - Manual Antimicrobial Susceptibility Test Systems",
        "comparison_with_predicate": "Similarities: Intended Use, Media, Inoculation, Reading, Result. Differences: Antibiotic, Incubation."
    },
    "K153278.txt": {
        "applicant": "Andon Health Co., Ltd",
        "conclusion": "The submitted information in this premarket notification is complete and supports a substantial equivalence decision.",
        "classification": "II",
        "panel": "Chemistry",
        "measurand": "Capillary Whole Blood Glucose from the fingertip palm, forearm, upper arm, calf or thigh",
        "submission_number": "k153278",
        "intended_use": "The iHealth Wireless Gluco-Monitoring System is intended to be used for the quantitative measurement of glucose (sugar) in fresh capillary whole blood samples drawn from the fingertip, palm, forearm, upper arm, calf, or thigh. The iHealth Wireless Gluco-Monitoring System is intended to be used by a single person and should not be shared. The iHealth Wireless Gluco-Monitoring System is intended for self-testing outside the body (in vitro diagnostic use) by people with diabetes at home as an aid to monitor the effectiveness of diabetes control. The iHealth Wireless Gluco-Monitoring System should not be used for the diagnosis of or screening of diabetes or for neonatal use.",
        "regulation_section": "21 \u00a7 862.1345",
        "product_code": "NBW",
        "comparison_with_predicate": "Similarities: Same intended use, sample source, model, enzyme, measuring range, hematocrit range, connectivity to meter, test strip calibration, dimensions, and mobile app name. Differences: Mobile App version V3.4.3, Compatible OS version iOS 7, 8, 9, Android 4.0, 4.2, 4.4, 5.0, and additional phone platforms."
    },
    "K181525.txt": {
        "applicant": "Siemens Healthcare Diagnostics Product GmbH",
        "conclusion": "The submitted information in this premarket notification is complete and supports a substantial equivalence decision.",
        "classification": "Class II",
        "panel": "Hematology (81)",
        "measurand": "Free Protein S Antigen (%)",
        "submission_number": "K181525",
        "intended_use": "For the quantitative determination of free protein S antigen in human plasma collected from venous blood samples in 3.2% sodium citrate tubes on the Sysmex CS- 5100 analyzer. As an aid in the diagnosis of protein S deficiency in patients who are suspected of free protein S deficiency. The performance of this device has not been established in neonate and pediatric patient populations.",
        "regulation_section": "21 CFR 864.7290, Factor deficiency test",
        "product_code": "GGP, Test, qualitative and quanititative factor deficiency",
        "comparison_with_predicate": "Similarities: Intended use, Test principle, Sample type, Measuring range. Differences: Buffer, Shelf-life stability, On-board stability, High dose hook effect."
    },
    "K190223.txt": {
        "applicant": "Microbiologics, Inc.",
        "conclusion": "The submitted information in this premarket notification is complete and supports a substantial equivalence decision",
        "classification": "Class II (Special Controls)",
        "panel": "(83) Microbiology",
        "measurand": "Nucleic acids from inactivated Chlamydia trachomatis and Neisseria gonorrhoeae (positive control) and from human epithelial cells (negative control).",
        "submission_number": "K190223",
        "intended_use": "The Cepheid Xpert CT/NG Control Panel is intended for use as an external assayed positive and negative quality control to monitor the performance of in vitro laboratory nucleic acid testing procedures for the qualitative detection of Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG) performed with the Cepheid Xpert CT/NG assay on the GeneXpert Instrument System. The controls consist of cultured and inactivated Chlamydia trachomatis and Neisseria gonorrhoeae as the positive control and human cells as the negative control. The Cepheid Xpert CT/NG Control Panel is not intended to replace manufacturer controls provided with the device.",
        "regulation_section": "21 CFR 866.3920, Assayed quality control material for clinical microbiology assays",
        "product_code": "PMN",
        "comparison_with_predicate": "The Cepheid Xpert CT/NG Control Panel is intended for use as an external assayed positive and negative quality control to monitor the performance of in vitro laboratory nucleic acid testing procedures for the qualitative detection of Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG) performed with the Cepheid Xpert CT/NG assay on the GeneXpert Instrument System. The controls consist of cultured and inactivated Chlamydia trachomatis and Neisseria gonorrhoeae as the positive control and human cells as the negative control. The Cepheid Xpert CT/NG Control Panel is not intended to replace manufacturer controls provided with the device. External assayed positive and negative quality control materials to monitor the performance of in vitro laboratory nucleic acid testing procedures for the qualitative detection of Group B Streptococcus (GBS) performed with the Cepheid Xpert GBS LB Assay on the GeneXpert Instrument System. The controls comprise cultured and inactivated Streptococcus agalactiae as the positive control and Lactobacillus acidophilus as the negative control. The Cepheid Xpert GBS LB Control Panel is not intended to replace the manufacturer controls provided with the device."
    },
    "K162042.txt": {
        "applicant": "OptiScan Biomedical Corporation",
        "conclusion": "The submitted information in this premarket notification is complete and supports a substantial equivalence decision.",
        "classification": "II",
        "panel": "General Hospital",
        "measurand": "Plasma glucose from central venous catheter blood draw",
        "submission_number": "k162042",
        "intended_use": "The OptiScanner 5000 Glucose Monitoring System is an automated, bedside glucose monitoring device indicated for detecting trends and tracking patterns in persons (age 18 and older) in the surgical intensive care unit. The system collects a venous whole blood sample via connection to a central venous catheter, centrifuges the sample, and measures the plasma glucose concentration. It is not intended for the screening or diagnosis of diabetes mellitus but is indicated for use in determining dysglycemia. The OptiScanner 5000 Glucose Monitoring System is for in vitro diagnostic use.",
        "regulation_section": "21 CFR \u00a7880.5725",
        "product_code": "LZF",
        "comparison_with_predicate": "Similar"
    },
    "K171770.txt": {
        "applicant": "Roche Molecular Systems, Inc.",
        "conclusion": "The submitted information in this premarket notification is complete and supports a substantial equivalence decision.",
        "classification": "II",
        "panel": "Microbiology (83)",
        "measurand": "tcdB gene of toxigenic Clostridium difficile",
        "submission_number": "K171770",
        "intended_use": "The cobas Cdiff Nucleic acid test for use on the cobas Liat System is an automated, qualitative in vitro diagnostic test, that utilizes real-time polymerase chain reaction (PCR), for the detection of the toxin B (tcdB) gene of toxigenic Clostridium difficile in unformed (liquid or soft) stool specimens obtained from patients suspected of having C. difficile infection (CDI). The cobas Cdiff Nucleic acid test for use on the cobas Liat System is intended for use as an aid in the diagnosis of CDI in humans in conjunction with clinical and epidemiological risk factors.",
        "regulation_section": "21 CFR 866.3130, Clostridium difficile toxin gene amplification assay",
        "product_code": "OZN, OOI",
        "comparison_with_predicate": "Similarities: Sample type - Unformed soft stool specimens, Amplification Technology - Real-time PCR, Detection Technology - TaqMan probes with fluorescent dyes, Assay target - C. difficile Toxin B gene (tcdB), Sample extraction - Automated magnetic bead-based nucleic acid extraction. Differences: Instrument platform - cobas Liat system vs cobas 4800 system, Samples/controls per run - One sample per run vs Up to 24 or 96 samples per run, Test duration - Results within ~20 minutes after specimen loading vs Results within 2.5 hours after specimen loading, Internal control design - A whole organism, gram-positive bacterial control (chemically inactivated Bacillus thuringiensis israelensis) vs Lambda phage with encapsulated internal control sequence."
    },
    "K171641.txt": {
        "applicant": "Mesa Biotech, Inc.",
        "conclusion": "The submitted information in this premarket notification is complete and supports a substantial equivalence decision.",
        "classification": "Class II",
        "panel": "Microbiology (83)",
        "measurand": "Influenza A PB2 RNA, Influenza B Matrix RNA",
        "submission_number": "K171641",
        "intended_use": "The Accula Flu A/Flu B Test performed on the Accula Dock is a molecular in vitro diagnostic test utilizing polymerase chain reaction (PCR) and lateral flow technologies for the qualitative, visual detection and differentiation of influenza A and influenza B viral RNA. The Accula Flu A/Flu B Test uses a nasal swab specimen collected from patients with signs and symptoms of respiratory infection. The Accula Flu A/Flu B assay is intended as an aid in the diagnosis of influenza infection in conjunction with clinical and epidemiological risk factors. The assay is not intended to detect the presence of influenza C virus.",
        "regulation_section": "21 CRF 866.3980, Respiratory viral panel multiplex nucleic acid assay",
        "product_code": "OZE - Influenza A and Influenza B Multiplex Nucleic Acid Assay",
        "comparison_with_predicate": "Table 1: Similarities Between Accula Flu A/Flu B and Predicate Device Similarities Item Mesa Biotech Accula Flu A/Flu B Test Alere i Influenza A&B Test Assay Targets Influenza A and Influenza B virus Same Sample Type Nasal Swab Same Assay Results Qualitative Same Intended Users and Locations Clinical Lab and Point of Care Same Nucleic Acid Purification No Same Influenza A Target PB2 Gene Same Internal Control Yes Same Positive and Negative Control Swabs Yes Same Table 2: Differences Between Accula Flu A/Flu B and Predicate Device Differences Item Mesa Biotech Accula Flu A/Flu B Test Alere i Influenza A&B Test Intended Use The Accula Flu A/Flu B Test performed on the Accula Dock is a molecular in vitro diagnostic test utilizing polymerase chain reaction (PCR) and lateral flow technologies for the qualitative, visual detection and differentiation of influenza A and influenza B viral RNA. The Accula Flu A/Flu B Test uses a nasal swab specimen collected from patients with signs and symptoms of respiratory infection. The Accula Flu A/Flu B assay is intended as an aid in the diagnosis of influenza infection in conjunction with clinical and epidemiological risk factors. The assay is not intended to detect the presence of influenza C virus. Negative results do not preclude influenza virus infection and should not be used as the sole basis for treatment or other patient management decisions. Performance characteristics for influenza A were established during the 2016-2017 influenza season. When other influenza A viruses are emerging, performance characteristics may vary. If infection with a novel influenza A virus is suspected based on current clinical and epidemiological screening criteria recommended by public health authorities, specimens should be collected with appropriate infection control precautions for novel virulent influenza viruses and sent to state or local public health department for testing. Viral culture should not be attempted in these cases unless a BSL 3+ facility is available to receive and culture specimens. The Alere\u2122 i Influenza A & B assay performed on the Alere\u2122 i Instrument is a rapid molecular in vitro diagnostic test utilizing an isothermal nucleic acid amplification technology for the qualitative detection and discrimination of influenza A and B viral RNA in nasal swabs from patients with signs and symptoms of respiratory infection. It is intended for use as an aid in the differential diagnosis of influenza A and B viral infections in humans in conjunction with clinical and epidemiological risk factors. The assay is not intended to detect the presence of influenza C virus. Negative results do not preclude influenza virus infection and should not be used as the sole basis for diagnosis, treatment or other patient management decisions. Performance characteristics for influenza A were established during the 2012-2013 influenza season when influenza A/H3 and A/H1N1 pandemic were the predominant influenza A viruses in circulation. When other influenza A viruses are emerging, performance characteristics may vary. If infection with a novel influenza A virus is suspected based on current clinical and epidemiological screening criteria recommended by public health authorities, specimens should be collected with appropriate infection control precautions for novel virulent Influenza viruses and sent to state or local health department for testing. Viral culture should not be attempted in these cases unless a BSL 3+ facility is available to receive and culture specimens. Influenza B Target Matrix Gene PA Gene Assay Technology PCR amplification and visual identification of amplified products by hybridization to a test strip Isothermal nucleic acid amplification and detection of amplified products using molecular beacon probes Detection Dyed microparticle conjugates specifically detect amplified products Fluorescently-labeled molecular beacons identify amplified RNA targets Instrument Amplification controlled by the Accula Dock Amplification performed on the Alere i Instrument Results Interpretation Visual interpretation of colored lines on a test strip Optical detection of fluorescence by the Alere i instrument"
    },
    "K180559.txt": {
        "applicant": "ELITechGroup Inc. Molecular Diagnostics",
        "conclusion": "The submitted information in this premarket notification is complete and supports a substantial equivalence decision.",
        "classification": "Class II",
        "panel": "83 - Microbiology",
        "measurand": "Target DNA Sequences from conserved regions of Herpes Simplex Virus Type 1 (HSV-1) and Herpes Simplex Virus Type 2 (HSV-2)",
        "submission_number": "K180559",
        "intended_use": "The HSV 1&2 ELITe MGB\u00ae Assay is a real-time polymerase chain reaction (PCR) based qualitative in vitro diagnostic test for the direct detection and differentiation of Herpes Simplex Virus 1 and 2 (HSV-1 and HSV-2) DNA in cutaneous or mucocutaneous lesion swab specimens from patients with signs and symptoms of HSV-1 or HSV-2 infection. This test is an aid in the differential diagnosis of HSV-1 and HSV-2 infections. The HSV 1&2 ELITe MGB Assay is not FDA cleared for use with cerebrospinal fluid (CSF) specimens. The assay is not intended to be used for prenatal screening or for screening blood or blood products.",
        "regulation_section": "21CFR 866.3309",
        "product_code": "PGI",
        "comparison_with_predicate": "Similarities: Indications For Use, Extraction Technology, Amplification Technology, Samples Type. Differences: Assay Targets, Detection Technology."
    },
    "K160538.txt": {
        "applicant": "Sysmex America Inc.",
        "conclusion": "The submitted information in this premarket notification is complete and supports a substantial equivalence decision.",
        "classification": "Class II",
        "panel": "Hematology (81)",
        "measurand": "WBC, RBC, HGB, HCT, MCV, MCH, MCHC, PLT, NEUT%/#, LYMPH%/#, MONO%/#, EO%/#, BASO%/#, IG%/#, RDW-CV, RDW-SD, MPV, RET%/#, IRF, RET-He, WBC-BF, RBC-BF, MN%/#, PMN%/#, TC-BF#",
        "submission_number": "K160538",
        "intended_use": "The Sysmex XN-L analyzer is a quantitative multi-parameter automated hematology analyzer intended for in vitro diagnostic use in screening patient populations found in clinical laboratories. The XN-L analyzer classifies and enumerates the following parameters in venous and capillary whole blood: WBC, RBC, HGB, HCT, MCV, MCH, MCHC, PLT, NEUT%/#, LYMPH%/#, MONO%/#, EO%/#, BASO%/#, IG%/#, RDW-CV, RDW-SD, MPV, RET%/#, IRF, RET-He and has a Body Fluid mode for body fluids. The Body Fluid mode enumerates the WBC-BF, RBC-BF, MN%/#, PMN%/#, and TC-BF# parameters in cerebrospinal, peritoneal, pleural, and synovial fluids.",
        "regulation_section": "21 CFR 864.5220, Automated differential cell counter",
        "product_code": "GKZ, Counter, differential cell",
        "comparison_with_predicate": "The Sysmex XN-L analyzer is similar to the Sysmex XN-Series (XN-10, XN-20) Automated Hematology Analyzer, K112605, in intended use, specimen type, test principle, parameters, reagents, analysis modes, sample aspiration/fluidic pathway, measuring channels, controls/calibrators/linearity material, cleaning detergent, and software/hardware."
    },
    "K151923.txt": {
        "applicant": "bioM\u00e9rieux, Inc.",
        "conclusion": "The submitted information in this premarket notification is complete and supports a substantial equivalence decision.",
        "classification": "II",
        "panel": "83 Microbiology",
        "measurand": "The VITEK 2 AST Yeast card contains the following concentration of Micafungin: 0.06, 0.25, 1 and 4\u03bcg/mL. The MIC result reporting range for the VITEK 2 card is \u2264 0.06 - \u22658 \u00b5g/ml.",
        "submission_number": "K151923",
        "intended_use": "The VITEK\u00ae 2 Antimicrobial Susceptibility Test (AST) is intended to be used with the VITEK\u00ae 2 Systems for the automated quantitative or qualitative susceptibility testing of isolated colonies for the most clinically significant aerobic gram-negative bacilli, Staphylococcus spp., Enterococcus spp., Streptococcus spp. and clinically significant yeast.",
        "regulation_section": "21 CFR 866.1640, Antimicrobial Susceptibility Test Powder",
        "product_code": "NGZ \u2013 Susceptibility Test Plate, Antifungal",
        "comparison_with_predicate": "Similarities: Intended Use, Test Methodology, Inoculum, Test Card, Instrument, Analysis algorithm. Differences: Antimicrobial Agent, Antimicrobial Concentrations."
    },
    "K182472.txt": {
        "applicant": "Microbiologics, Inc.",
        "conclusion": "The submitted information in this premarket notification is complete and supports a substantial equivalence decision.",
        "classification": "Class II (Special Controls)",
        "panel": "83 - Microbiology",
        "measurand": "Nucleic acid quality control material from inactivated Streptococcus agalactiae and Lactobacillus acidophilus bacterial cultures for detection of Streptococcus agalactiae (Group B Streptococcus positive control) and Lactobacillus acidophilus (negative control).",
        "submission_number": "K182472",
        "intended_use": "The Cepheid Xpert GBS LB Control Panel is intended for use as external assayed positive and negative quality control materials to monitor the performance of in vitro laboratory nucleic acid testing procedures for the qualitative detection of Group B Streptococcus (GBS) performed with the Cepheid Xpert GBS LB Assay on the GeneXpert Instrument System. The controls comprise cultured and inactivated Streptococcus agalactiae as the positive control and Lactobacillus acidophilus as the negative control. The Cepheid Xpert GBS LB Control Panel is not intended to replace the manufacturer controls provided with the device.",
        "regulation_section": "21 CFR 866.3920: Assayed quality control material for clinical microbiology assays",
        "product_code": "PMN: Assayed external control material for microbiology nucleic acid amplification assays",
        "comparison_with_predicate": "The Cepheid Xpert GBS LB Control Panel is compared with the Bio-Rad Amplichek II. Both are external assayed quality control materials to monitor the performance of in vitro laboratory nucleic acid testing procedures. The Cepheid Xpert GBS LB Control Panel is specifically for the qualitative detection of Group B Streptococcus (GBS) while the Bio-Rad Amplichek II is for Methicillin Resistant Staphylococcus aureus, Methicillin Sensitive Staphylococcus aureus, Clostridium difficile, and Vancomycin-resistant Enterococci."
    },
    "K162688.txt": {
        "applicant": "Siemens Healthcare Diagnostics Product GmbH",
        "conclusion": "The submitted information in this premarket notification is complete and supports a substantial equivalence decision.",
        "classification": "Class II",
        "panel": "Hematology (81)",
        "measurand": "Factor V activity using Coagulation Factor V Deficient Plasma with Dade\u00ae Innovin\u00ae; factor VII activity using Coagulation Factor VII Deficient Plasma with Dade\u00ae Innovin\u00ae; protein C activity using Protein C Reagent and protein C activity using Berichrom\u00ae Protein C. All measurands are reported as percent (%) of norm.",
        "submission_number": "K162688",
        "intended_use": "The Sysmex CS-2100i is a fully automated blood coagulation analyzer intended for in vitro diagnostic use using plasma collected from venous blood samples in 3.2% sodium citrate tubes to analyze clotting, chromogenic and immunoassay methods in the clinical laboratory.",
        "regulation_section": "21 CFR 864.5425, Multipurpose system for in vitro coagulation studies",
        "product_code": "JPA, System, multipurpose for in vitro coagulation studies",
        "comparison_with_predicate": "The intended use of the Sysmex\u00ae CA-1500 is as a fully automated, computerized blood plasma coagulation analyzer for in vitro diagnostic use in clinical laboratories. The instrument uses citrated human plasma to perform the following parameters and calculated parameters: Clotting Analysis Parameters: Prothrombin Time (PT); Activated Partial Thromboplastin Time (APTT); Fibrinogen (Clauss); Batroxobin Time; Extrinsic Factors (II, V, VII, X); Intrinsic Factors (VIII, IX, XI, XII); Protein C Chromogenic Analysis Parameters: Antithrombin III; Factor VIII; Plasminogen; Heparin; Protein C; \u03b12-Antiplasmin Immunologic Analysis Parameters: D-dimer Calculated Parameters: PT Ratio; PT INR; PT %; Derived Fibrinogen; Factor Assays % Activity"
    },
    "K190332.txt": {
        "applicant": "Leica Biosystems Imaging, Inc.",
        "conclusion": "The submitted information in this premarket notification is complete and supports a substantial equivalence decision.",
        "classification": "Class II (special controls)",
        "panel": "88 - Pathology",
        "measurand": "Not applicable",
        "submission_number": "K190332",
        "intended_use": "The Aperio AT2 DX System is an automated digital slide creation and viewing system. The Aperio AT2 DX System is intended for in vitro diagnostic use as an aid to the pathologist to review and interpret digital images of surgical pathology slides prepared from formalin-fixed paraffin embedded (FFPE) tissue. The Aperio AT2 DX System is not intended for use with frozen section, cytology, or non-FFPE hematopathology specimens.",
        "regulation_section": "21 CFR 864.3700",
        "product_code": "PSY",
        "comparison_with_predicate": "Similarities: Intended Use, Specimen type, Principle of operation, Device Components. Differences: Whole Slide Imaging Scanner, Graphical User Interface, Monitor Display."
    },
    "K151046.txt": {
        "applicant": "Meridian Bioscience, Inc.",
        "conclusion": "The submitted information in this premarket notification is complete and supports a substantial equivalence decision.",
        "classification": "Class II",
        "panel": "Microbiology (83)",
        "measurand": "Target DNA sequences from Herpes Simplex Virus type 1 (HSV-1) and Herpes Simplex Virus type 2 (HSV-2).",
        "submission_number": "K151046",
        "intended_use": "The illumigene HSV 1&2 DNA amplification assay, performed on the illumipro-10\u2122, is a qualitative in vitro diagnostic test for the direct detection and differentiation of herpes simplex virus type 1 (HSV-1) and herpes simplex virus type 2 (HSV-2) DNA in cutaneous and mucocutaneous lesion specimens from male and female patients suspected of Herpetic infections.",
        "regulation_section": "21 CFR 866.3309",
        "product_code": "PGI",
        "comparison_with_predicate": "Similarities DEVICE illumigene\u00ae HSV 1&2 DNA Amplification Assay K151046 PREDICATE Quidel Lyra\u2122 Direct HSV 1 + 2/VZV Assay K133448 Intended Use Qualitative in vitro diagnostic test for the direct detection and differentiation of herpes simplex virus type 1 (HSV-1) and herpes simplex virus type 2 (HSV-2) DNA in cutaneous and mucocutaneous lesion specimens from male and female patients suspected of Herpetic infections. Qualitative detection and differentiation of herpes simplex virus type 1, herpes simplex virus type 2, and varicella-zoster virus DNA isolated and purified from cutaneous or mucocutaneous lesion samples obtained from symptomatic patients suspected of active herpes simplex virus 1, herpes simplex virus 2 and/or varicella-zoster infection. Assay Results Qualitative Qualitative Indications for Use Professional Use Professional Use DNA Detected Herpes simplex virus type 1 Herpes simplex virus type 2 Herpes simplex virus type 1 Herpes simplex virus type 2 Varicella-zoster virus Typing of HSV-1 andHSV-2? Yes Yes Specimen Types Male and female cutaneous and mucocutaneous lesion swab specimens Male and female cutaneous and mucocutaneous lesion swab specimens Method DNA Amplification DNA Amplification Detection Instrument Instrument Differences DEVICE illumigene\u00ae HSV 1&2 DNA Amplification Assay K151046 PREDICATE Quidel Lyra\u2122 Direct HSV 1 + 2/VZV Assay K133448 Amplification Methodology Loop-Mediated Isothermal Amplification (LAMP) Multiplex Real-Time PCR Detection Methodology Turbidity Target-specific fluorescent-labeled hybridization probes Reagents/ Components The illumigene HSV 1&2 DNA Amplification Assay Kit contains illumigene Sample Preparation Apparatus III, illumigene HSV 1 Test Devices, illumigene HSV 2 Test Devices, Mineral Oil, illumigene Heat Treatment Tubes, and Transfer Pipettes. The Lyra\u2122 Direct HSV 1 + 2/VZV Assay kit consists of: - Rehydration Solution - Process Buffer Part M5050 (contains the PRC) - Lyra\u2122 Direct HSV 1 + 2/VZV Master Mix Part M5012 - Lyophilized Contents: o DNA polymerase enzyme o Primers and probes o dNTPs o Stabilizers . Instrumentation illumipro-10\u2122 Automated Isothermal Amplification and Detection System Life Technologies QuantStudio\u2122 Dx, the Applied Biosystems\u00ae 7500 Fast Dx, or the Cepheid SmartCycler\u00ae II System Reading Method Visible Light Transmission Fluorescence detection of dual-labeled hydrolysis probes, Ct values. Packaging Supplied as a kit; 25 tests per kit Supplied as a kit; 96 tests per kit. Kit Storage 2-30\u00b0C Reagents and Controls: 2-8\u00b0C VZV detection? No Yes"
    },
    "K172333.txt": {
        "applicant": "Siemens Healthcare Diagnostics Product GmbH",
        "conclusion": "The submitted information in this premarket notification is complete and supports a substantial equivalence decision.",
        "classification": "Class II: Factor V Leiden Assay; Coagulation Factor VIII Deficient Plasma; Coagulation Factor IX Deficient Plasma Class I: LA 1 Screening Reagent, LA 2 Confirmation Reagent, and LA Ratio",
        "panel": "Hematology (81)",
        "measurand": "Factor V Leiden activity with Factor V Leiden Assay; Factor VIII activity with Dade\u00ae Actin\u00ae FSL Activated PTT Reagent; Factor IX activity with Dade\u00ae Actin\u00ae FSL Activated PTT Reagent; Lupus Anticoagulant with LA 1 Screening Reagent; Lupus Anticoagulant with LA 2 Confirmation Reagent and Lupus Anticoagulant with LA Ratio.",
        "submission_number": "K172333",
        "intended_use": "The Sysmex\u00ae Automated Blood Coagulation Analyzer CS-5100 is a fully automated blood coagulation analyzer intended for in vitro diagnostic use using plasma collected from venous blood samples in 3.2% sodium citrate tubes to analyze clotting, chromogenic and immunoassay methods in the clinical laboratory.",
        "regulation_section": "Sysmex CS-5100 21 CFR 864.5425, Multipurpose system for in vitro coagulation studies Factor V Leiden Assay 21 CFR 864.7925, Partial thromboplastin time test Coagulation Factor VIII Deficient Plasma 21 CFR 864.7290, Factor deficiency test Coagulation Factor IX Deficient Plasma LA 1 Screening Reagent, LA 2 Confirmation Reagent, and LA Ratio 21 CFR 864.8950, Russell viper venom reagent",
        "product_code": "Sysmex CS-5100 JPA, System, multipurpose for in vitro coagulation studies Factor V Leiden Assay GGW, Test, Time, Partial Thromboplastin Coagulation Factor VIII Deficient Plasma GJT, Plasma, coagulation factor deficient Coagulation Factor IX Deficient Plasma LA 1 Screening Reagent, LA 2 Confirmation Reagent, and LA Ratio GIR, Reagent, Russell Viper Venom",
        "comparison_with_predicate": "The Sysmex CS-5100 is a fully automated blood coagulation analyzer intended for in vitro diagnostic use using plasma collected from venous blood samples in 3.2% sodium citrate tubes to analyze clotting, chromogenic and immunoassay methods in the clinical laboratory. The intended use of the Sysmex CA-1500 is as a fully automated, computerized blood plasma coagulation analyzer for in vitro diagnostic use in clinical laboratories."
    },
    "K152614.txt": {
        "applicant": "Cepheid",
        "conclusion": "The submitted information in this premarket notification is complete and supports a substantial equivalence decision.",
        "classification": "Class II",
        "panel": "83-Microbiology",
        "measurand": "Target DNA sequence of the following genes: blaKPC, blaNDM, blaVIM, blaOXA-48, and blaIMP",
        "submission_number": "K152614",
        "intended_use": "The Xpert\u00ae Carba-R Assay, performed on the GeneXpert\u00ae Instrument Systems, is a qualitative in vitro diagnostic test for the detection and differentiation of the blaKPC, blaNDM, blaVIM, blaOXA-48, and blaIMP gene sequences associated with carbapenem-non-susceptible pure colonies of Enterobacteriaceae, Acinetobacter baumannii, or Pseudomonas aeruginosa grown on blood agar or MacConkey agar. The test utilizes automated real-time polymerase chain reaction (PCR).",
        "regulation_section": "21 CFR 866.1640 (Antimicrobial susceptibility test powder)",
        "product_code": "PMY- System, nucleic acid amplification test, DNA, carbapenem non-susceptible gram negative organism, colony OOI-Real-time nucleic acid amplification system",
        "comparison_with_predicate": "Similarities: Fully-automated nucleic acid amplification (DNA); real-time PCR. Differences: Sample Type - Bacterial isolates from culture vs Rectal swabs; Assay Targets - Detects blaKPC, blaNDM, blaVIM, blaOXA-48, and blaIMP gene sequences vs Detects gene sequences for the vanA encoded resistance to vancomycin/teicoplanin."
    },
    "K143736.txt": {
        "applicant": "IMMCO Diagnostics, Inc.",
        "conclusion": "The submitted information in this premarket notification is complete and supports a substantial equivalence decision.",
        "classification": "Class II",
        "panel": "Immunology (82)",
        "measurand": "Rheumatoid Factors (RF) IgA, IgG, IgM, and Rheumatoid Factor Total",
        "submission_number": "K143736",
        "intended_use": "Enzyme linked immunoassay (ELISA) for the qualitative or semi-quantitative detection of Rheumatoid Factor IgA, IgG, and IgM antibodies in human serum to aid in the diagnosis of rheumatoid arthritis (RA) in conjunction with other laboratory tests and clinical findings.",
        "regulation_section": "21 CFR \u00a7866.5775: Rheumatoid factor immunological test system",
        "product_code": "DHR: System, Test, Rheumatoid Factor",
        "comparison_with_predicate": "Similarities: Intended Use/Indication for Use, Test Principle, Instrumentation, Analyte, Sample Type, Sample Dilution, Kit Components, Capture Antigen, Detection Reagents, Substrate, Incubation Times, Stop Solution, Controls. Differences: Measurement Type, Wash buffer, Calibrators, Reagent Stability, Cut-offs, Linear Ranges, Limits of Blank, Limits of Detection, Traceability."
    },
    "K162705.txt": {
        "applicant": "Maine Standards Company LLC",
        "conclusion": "The submitted information in this premarket notification is complete and supports a substantial equivalence decision.",
        "classification": "Class II",
        "panel": "Hematology (81)",
        "measurand": "D-dimer",
        "submission_number": "K162705",
        "intended_use": "VALIDATE\u00ae D-Dimer Calibration Verification/Linearity Test Kit solutions are assayed quality control materials intended for in vitro diagnostic use in the quantitative determination of linearity, calibration verification and verification of reportable range for the following analyte: D-Dimer in a clinical laboratory setting by laboratory personnel. The product is intended for use with quantitative assays on the indicated analyzers specified in the labeling.",
        "regulation_section": "21 CFR 864.5425, Multipurpose system for in vitro coagulation studies",
        "product_code": "GGN, Plasma, Coagulation Control",
        "comparison_with_predicate": "There is no difference between the subject device and the predicate."
    },
    "K192815.txt": {
        "applicant": "Roche Diagnostics",
        "conclusion": "The submitted information in this premarket notification is complete and supports a substantial equivalence decision.",
        "classification": "Class II",
        "panel": "Microbiology",
        "measurand": "Procalcitonin (PCT)",
        "submission_number": "K192815",
        "intended_use": "Immunoassay for the in vitro quantitative determination of PCT (procalcitonin) in human serum and plasma (K2 \u2013EDTA, K3-EDTA and Li-Heparin).",
        "regulation_section": "21 CFR 866.3215 - Device to detect and measure non-microbial analyte(s) in human clinical specimens to aid in assessment of patients with suspected sepsis",
        "product_code": "PRI",
        "comparison_with_predicate": "Same with the exception of intended analyzers, Elecsys BRAHMS PCT with biotin update is only intended for use on cobas e immunoassay analyzers."
    },
    "K183324.txt": {
        "applicant": "ThermoFisher Scientific",
        "conclusion": "The submitted information in this premarket notification is complete and supports a substantial equivalence decision.",
        "classification": "Class II",
        "panel": "83, Microbiology",
        "measurand": "Omadacycline in the dilution range of 0.008 \u2013 32 \u00b5g/mL.",
        "submission_number": "K183324",
        "intended_use": "The Sensititre Haemophilus influenzae/Streptococcus pneumoniae plates are in vitro diagnostic products for clinical susceptibility testing of Haemophilus influenzae, Streptococcus pneumoniae, and Streptococcus species.",
        "regulation_section": "866.1640 Antimicrobial Susceptibility Test Powder",
        "product_code": "JWY \u2013 Manual Antimicrobial Susceptibility Test System, LRG \u2013 Instrument for Auto Reader and Instrumentation of Overnight Susceptibility Systems, LTT \u2013 Panels, Test, Susceptibility, Antimicrobial",
        "comparison_with_predicate": "Sensititre Haemophilus/Streptococcus pneumoniae (HP) MIC Plates with Ertapenem"
    },
    "K172745.txt": {
        "applicant": "IMMCO Diagnostics, Inc.",
        "conclusion": "The submitted information in this premarket notification is complete and supports a substantial equivalence decision.",
        "classification": "Class II",
        "panel": "Immunology (82)",
        "measurand": "IgG Anti-Nuclear Antibodies (ANA)",
        "submission_number": "K172745",
        "intended_use": "The ImmuGlo HEp-2 Elite IFA is an indirect immunofluorescence antibody test for the qualitative or semi-quantitative detection of anti-nuclear antibodies (ANA) of the IgG isotype in human serum utilizing standard HEp-2 cells and engineered HEp-2 cells as a substrate. The ImmuGlo HEp-2 Elite IFA is intended for use as an aid in the diagnosis of systemic rheumatic diseases in conjunction with other clinical and laboratory findings.",
        "regulation_section": "21 CFR \u00a7866.5100 \u2012 Antinuclear antibody immunological test system",
        "product_code": "DHN \u2012 Antinuclear Antibody, Indirect Immunofluorescent, Antigen, Control",
        "comparison_with_predicate": "Similarities: Intended Use, Methodology, Matrix, Detection of antibodies, Component Set, Conjugate, Screening dilution, Reading, Storage. Differences: Substrate, Positive control."
    },
    "K161510.txt": {
        "applicant": "bioM\u00e9rieux, Inc.",
        "conclusion": "The submitted information in this premarket notification is complete and supports a substantial equivalence decision.",
        "classification": "Class II",
        "panel": "Microbiology (83)",
        "measurand": "The VITEK 2 AST-Gram Negative card contains the following concentrations of Ceftolozane/Tazobactam: 0.5/4, 1/4, 4/4, 8/4, and 32/4 \u00b5g/mL (equivalent standard method concentration by efficacy in \u00b5g/mL). The MIC result reporting range for the card is \u22640.25 - \u226532 \u00b5g/mL.",
        "submission_number": "K161510",
        "intended_use": "The VITEK\u00ae2 Antimicrobial Susceptibility Test (AST) is intended to be used with the VITEK\u00ae2 Systems for the automated quantitative or qualitative susceptibility testing of isolated colonies for the most clinically significant aerobic gram-negative bacilli, Staphylococcus spp., Enterococcus spp., Streptococcus spp. and clinically significant yeast.",
        "regulation_section": "221 CFR 866.1645 Fully Automated Short-Term Incubation Cycle Antimicrobial Susceptibility System",
        "product_code": "LON - Fully automated short-term incubation cycle antimicrobial susceptibility system. LTW \u2013 Susceptibility Test Cards, Antimicrobial LTT \u2013 Panels, Test, Susceptibility, Antimicrobial",
        "comparison_with_predicate": "Similarities: Intended Use, Test Method, Inoculum, Test Card, Instrument, Detection Method, Report. Differences: Antimicrobial, Antimicrobial Concentration, Algorithm Analysis, Reporting Range."
    },
    "K181915.txt": {
        "applicant": "iXensor Co., LTD.",
        "conclusion": "The submitted information in this premarket notification is complete and supports a substantial equivalence decision.",
        "classification": "II",
        "panel": "Hematology (81)",
        "measurand": "Glycosylated hemoglobin (HbA1c)",
        "submission_number": "k181915",
        "intended_use": "The PixoTest POCT System, consisting of PixoTest POCT Analyzer and PixoTest A1c Test Kit, is used for the quantitative measurement of glycated hemoglobin (%HbA1c) in venous whole blood samples. It is an in-vitro diagnostic system intended to monitor long term glycemic control in individuals previously diagnosed with diabetes mellitus. The PixoTest POCT System is intended for clinical laboratory and Point-of-Care Professional use. It is not intended for use in the diagnosis of or screening for diabetes and is not intended for use on neonates.",
        "regulation_section": "21 CFR 864.7470",
        "product_code": "LCP",
        "comparison_with_predicate": "Similarities & Differences Item Device PixoTest POCT System (k181915) Predicate SD A1cCare System (k140827) Indications for Use Quantitative determination of percent hemoglobin A1c to monitor long term glycemic control in individuals previously diagnosed with diabetes. Same Test Principle Immunoassay Same Intended Use Environment Clinical laboratories and point-of-care settings Same Measuring Range 4.0-15.0% Same Sample Type Venous whole blood (anticoagulated with K2-EDTA, sodium heparin, lithium heparin, or sodium fluoride) Fingerstick capillary or venous whole blood (anticoagulated with K2-EDTA, sodium heparin, lithium heparin, or sodium fluoride) Sample Volume 5 \u03bcL Same Sample Pretreatment tools Spoit, buffer tube Same"
    },
    "K182389.txt": {
        "applicant": "Sysmex America Inc.",
        "conclusion": "The submitted information in this premarket notification is complete and supports a substantial equivalence decision.",
        "classification": "Class II",
        "panel": "Hematology (81)",
        "measurand": "WBC, RBC, HGB, HCT, MCV, MCH, MCHC, PLT, NEUT%/#, LYMPH%/#, MONO%/#, EO%/#, BASO%/#, IG%/#, RDW-CV, RDW-SD, MPV, RET%/#, IRF, RET-He",
        "submission_number": "K182389",
        "intended_use": "The Sysmex XN-L analyzer is a quantitative multi-parameter automated hematology analyzer intended for in vitro diagnostic use in screening patient populations found in clinical laboratories. The XN-L analyzer classifies and enumerates the following parameters in venous and capillary whole blood: WBC, RBC, HGB, HCT, MCV, MCH, MCHC, PLT, NEUT%/#, LYMPH%/#, MONO%/#, EO%/#, BASO%/#, IG%/#, RDW-CV, RDW-SD, MPV, RET%/#, IRF, RET-He and has a Body Fluid mode for body fluids. The Body Fluid mode enumerates the WBC-BF, RBC-BF, MN%/#, PMN%/#, and TC-BF# parameters in cerebrospinal, peritoneal, pleural, and synovial fluids. Whole blood should be collected in K2 or K3EDTA anticoagulant and peritoneal, pleural, and synovial fluids in K2EDTA anticoagulant to prevent clotting of fluid. The use of anticoagulants with CSF specimens is neither required nor recommended.",
        "regulation_section": "21 CFR 864.5220, Automated differential cell counter",
        "product_code": "GKZ, Counter, Differential Cell",
        "comparison_with_predicate": "Similarities: Specimen Type - Whole Blood and Body Fluids (CSF and peritoneal, pleural, synovial fluids); Test Principle - Hydro Dynamic Focusing (DC Detection), flow cytometry method using a semiconductor laser and SLS hemoglobin method. Differences: Parameters - Not Available; Reagents - Not Available; Measuring Channels - Not Available; Controls/Calibrators - Not Available; Throughput - Whole Blood Mode 60 samples/hour maximum depending on mode used. Body Fluid Mode 30 samples/hour maximum; Sample Aspiration Volumes - Sampler Mode - 25 \u03bcL Manual (Closed Cap) Mode - 25 \u03bcL Manual (Open Cap) Mode - 25 \u03bcL Dilution Mode - 70 \u03bcL Body Fluid Mode - 70 \u03bcL"
    },
    "K183415.txt": {
        "applicant": "bioM\u00e9rieux, Inc.",
        "conclusion": "The submitted information in this premarket notification is complete and supports a substantial equivalence decision.",
        "classification": "Class II",
        "panel": "83 Microbiology",
        "measurand": "Imipenem 0.25 \u2013 16 \u00b5g/mL",
        "submission_number": "K183415",
        "intended_use": "The VITEK 2 Gram-negative Susceptibility Card is intended for use with the VITEK 2 Systems in clinical laboratories as an in vitro test to determine the susceptibility of clinically significant aerobic Gram-negative bacilli to antimicrobial agents when used as instructed.",
        "regulation_section": "21 CFR 866.1645 Fully Automated Short-Term Incubation Cycle Antimicrobial Susceptibility System",
        "product_code": "LON \u2013 Fully automated short-term incubation cycle antimicrobial susceptibility system",
        "comparison_with_predicate": "VITEK 2 AST-Gram Negative Imipenem is designed for antimicrobial susceptibility testing of Gram negative bacilli and is intended for use with the VITEK 2 and VITEK 2 Compact Systems as a laboratory aid in the determination of in vitro susceptibility to antimicrobial agents. VITEK 2 AST Gram Negative Imipenem is a quantitative test. Imipenem has been shown to be active against most strains of the microorganisms listed below, according to the FDA label for this antimicrobial. Active in vitro and in clinical infections: Acinetobacter spp. Citrobacter spp. Enterobacter cloacae/E. cloacae complex Escherichia coli Klebsiella spp. Pseudomonas aeruginosa"
    },
    "K173927.txt": {
        "applicant": "Roche Diagnostics",
        "conclusion": "The submitted information in this premarket notification is complete and supports a substantial equivalence decision.",
        "classification": "Class II (Special Controls)",
        "panel": "83 - (Microbiology)",
        "measurand": "Procalcitonin (PCT)",
        "submission_number": "K173927",
        "intended_use": "Immunoassay for the in vitro quantitative determination of PCT (procalcitonin) in human serum and plasma (K2 \u2013EDTA, K3-EDTA and Li-Heparin). The electrochemiluminescence immunoassay \u201cECLIA\u201d is intended for use on Elecsys and cobas e immunoassay analyzers. Used in conjunction with other laboratory findings and clinical assessments, Elecsys BRAHMS PCT is intended for use as follows: to aid in the risk assessment of critically ill patients on their first day of ICU admission for progression to severe sepsis and septic shock, to determine the change in PCT level over time as an aid in assessing the cumulative 28-day risk of all-cause mortality for patients diagnosed with severe sepsis or septic shock in the ICU or when obtained in the emergency department or other medical wards prior to ICU admission, to aid in decision making on antibiotic therapy, for inpatients or patients in the emergency department with suspected or confirmed lower respiratory tract infections (LRTI) \u2013 defined as community-acquired pneumonia (CAP), acute bronchitis, and acute exacerbation of chronic obstructive pulmonary disease (AECOPD), to aid in decision making on antibiotic discontinuation for patients with suspected or confirmed sepsis.",
        "regulation_section": "21 CFR 866.3215; Device to detect and measure non-microbial analyte(s) in human clinical specimens to aid in assessment of patients with suspected sepsis",
        "product_code": "PMT",
        "comparison_with_predicate": "The Elecsys BRAHMS PCT assay is a two-step sandwich immunoassay with streptavidin microparticles and an electrochemiluminescence detection system. The test system reagents contain a biotinylated monoclonal PCT-specific antibody and a ruthenium labeled monoclonal PCT-specific antibody. The BRAHMS PCT sensitive KRYPTOR assay is a homogeneous sandwich immunoassay for detection of PCT in human serum or plasma. The measuring principle is based on Time-Resolved Amplified Cryptate Emission (TRACE) technology, which measures the signal that is emitted from an immunocomplex with time delay."
    },
    "K172109.txt": {
        "applicant": "Liofilchem s.r.l.",
        "conclusion": "The submitted information in this premarket notification is complete and supports a substantial equivalence decision.",
        "classification": "II",
        "panel": "83 \u2013 Microbiology",
        "measurand": "Erythromycin 0.016-256 \u03bcg/mL",
        "submission_number": "K172109",
        "intended_use": "The Liofilchem MIC Test Strip (MTS) is a quantitative method intended for the in vitro determination of antimicrobial susceptibility of bacteria.",
        "regulation_section": "866.1640 Antimicrobial Susceptibility Test Powder",
        "product_code": "JWY - Manual Antimicrobial Test Systems",
        "comparison_with_predicate": "Similarities: Intended Use, Media, Inoculation, Reading, Result. Differences: Antibiotic, Incubation."
    },
    "K150617.txt": {
        "applicant": "Roche Molecular Systems, Inc.",
        "conclusion": "The submitted information in this premarket notification is complete and supports a substantial equivalence decision.",
        "classification": "Class II",
        "panel": "Microbiology (83)",
        "measurand": "Target DNA sequences from Herpes Simplex Virus type 1 (HSV-1) and Herpes Simplex Virus type 2 (HSV-2)",
        "submission_number": "K150617",
        "intended_use": "The cobas\u00ae HSV 1 and 2 Test on the cobas\u00ae 4800 system is an automated, qualitative in vitro diagnostic test, that utilizes real-time polymerase chain reaction (PCR), for the direct detection and differentiation of Herpes simplex virus 1 and 2 (HSV-1 and HSV-2) DNA in clinician-collected, external anogenital lesion specimens from symptomatic male and female patients. The cobas\u00ae HSV 1 and 2 Test is intended for use as an aid in diagnosis of anogenital HSV-1 and HSV-2 infections in symptomatic patients.",
        "regulation_section": "21 CFR 866.3305",
        "product_code": "OQO",
        "comparison_with_predicate": "The performance of the cobas\u00ae HSV 1/2 Test was compared to the composite reference method comprised of culture using the ELVIS\u00ae HSV ID/Typing Test System (Diagnostic Hybrids, Inc.) and PCR followed by bidirectional sequencing."
    },
    "K151767.txt": {
        "applicant": "Siemens Healthcare Diagnostics Inc.",
        "conclusion": "The submitted information in this premarket notification is complete and supports a substantial equivalence decision.",
        "classification": "Class II",
        "panel": "Clinical Chemistry",
        "measurand": "Sodium, Potassium, Chloride, Albumin",
        "submission_number": "K151767",
        "intended_use": "The Trinidad CH System is an automated, clinical chemistry analyzer designed to perform in vitro diagnostic tests on clinical specimens. The system\u2019s chemical and immunochemical assay applications utilize photometric and ion selective electrode technology for clinical use.",
        "regulation_section": "21 CFR 862.1665",
        "product_code": "JGS",
        "comparison_with_predicate": "Siemens ADVIA 1800 Chemistry System including ISE and Albumin BCP Assays"
    },
    "K150144.txt": {
        "applicant": "Affinity Biologicals Inc.",
        "conclusion": "The submitted information in this premarket notification is complete and supports a substantial equivalence decision.",
        "classification": "Class II",
        "panel": "81 (Hematology)",
        "measurand": "Fibrinogen",
        "submission_number": "K150144",
        "intended_use": "The VisuCon-F Low Fibrinogen Control Plasma is an assayed control plasma prepared from de-fibrinated human plasma intended for use in the quality control of quantitative fibrinogen assays in the low abnormal range. The VisuCon-F Low Fibrinogen Control Plasma may be used with mechanical instruments in conjunction with appropriate commercial reagents for determining fibrinogen levels in plasma by the clotting method of Clauss. This plasma is intended \u201cFor In Vitro Diagnostic Use\u201d. The intended users of the VisuCon-F Low Fibrinogen Control Plasma are trained laboratory personnel working in clinical laboratories.",
        "regulation_section": "21 CFR \u00a7864.5425, Multipurpose system for in vitro coagulation studies",
        "product_code": "GGN, Plasma, Coagulation Control",
        "comparison_with_predicate": "Similarities: Intended Use, Analyte, Matrix. Differences: Storage, Open-Vial Stability, Packaging."
    },
    "K153137.txt": {
        "applicant": "Instrumentation Laboratory (IL) Co.",
        "conclusion": "The submitted information in this premarket notification is complete and supports a substantial equivalence decision.",
        "classification": "Class II",
        "panel": "Hematology (81)",
        "measurand": "Anti-PF4/Heparin Total Antibodies",
        "submission_number": "K153137",
        "intended_use": "HemosIL HIT-Ab(PF4-H) is a qualitative, fully automated, latex enhanced immunoassay for the detection of anti-platelet factor 4/heparin (PF4/H) antibodies. The assay is for use in human 3.2% or 3.8% citrated plasma on the ACL TOP\u00ae Family of instruments in a laboratory setting. The result provided by the assay should be interpreted as either positive or negative based on the assay cut-off (1.0 U/mL). The positive or negative result aids in determining the risk for heparin induced thrombocytopenia (HIT) when used in conjunction with other laboratory and clinical findings. Anti-PF4/Heparin antibodies are commonly found in patients with HIT. For use in adult population suspected of HIT. Not for use in isolation to exclude HIT. HemosIL HIT-Ab(PF4-H) Controls are for the Quality Control of the HemosIL HIT-Ab(PF4-H) assay as performed on the ACL TOP\u00ae Family of instruments. For prescription use.",
        "regulation_section": "21 CFR 864.7695, Platelet factor 4 radioimmunoassay; 21 CFR 864.5425, Multipurpose system for in vitro coagulation studies",
        "product_code": "LCO, Platelet factor 4 radioimmunoassay; GGN, Plasma, Coagulation Control",
        "comparison_with_predicate": "Similarities: Measurand - Anti-PF4/Heparin Total Antibodies; Detection Method - Absorbance (Turbimetric); Intended Use - HemosIL HIT-Ab(PF4-H) is a qualitative, fully automated, latex enhanced immunoassay for the detection of anti-platelet factor 4/heparin (PF4/H) antibodies. The assay is for use in human 3.2% or 3.8% citrated plasma on the ACL TOP\u00ae Family of instruments in a laboratory setting. The result provided by the assay should be interpreted as either positive or negative based on the assay cut-off (1.0 U/mL). The positive or negative result aids in determining the risk for heparin induced thrombocytopenia (HIT) when used in conjunction with other laboratory and clinical findings. Anti-PF4/Heparin antibodies are commonly found in patients with HIT. For use in adult population suspected of HIT. Not for use in isolation to exclude HIT. HemosIL HIT-Ab(PF4-H) Controls are for the Quality Control of the HemosIL HIT-Ab(PF4-H) assay as performed on the ACL TOP Family of instruments. For prescription use. Differences: Sample Types - Citrated human plasma only; Cut-off - Fixed clinical cut-off: \u2265 1.0 U/mL; Methodology - Latex-enhanced immuno-turbidimetric assay; Antibodies - Purified mouse monoclonal anti-PF4-Heparin; Controls - Controls sold separately: Low Level at or below the cut-off, High Level at abnormal anti-PF4/H antibody level."
    },
    "K170127.txt": {
        "applicant": "Hardy Diagnostics",
        "conclusion": "The submitted information in this premarket notification is complete and supports a substantial equivalence decision.",
        "classification": "Class II",
        "panel": "83 - Microbiology",
        "measurand": "Ceftolozane/Tazobactam, 30/10\u00b5g",
        "submission_number": "K170127",
        "intended_use": "HardyDisk AST Disks are used for semi-quantitative in vitro susceptibility testing by the agar diffusion test procedure (Kirby-Bauer) of rapidly growing and certain fastidious bacterial pathogens.",
        "regulation_section": "21 CFR 866.1620 Antimicrobial Susceptibility Test Disc",
        "product_code": "JTN \u2013 Susceptibility Test Disc, Antimicrobial",
        "comparison_with_predicate": "Same"
    },
    "K143548.txt": {
        "applicant": "Trividia Health, Inc.",
        "conclusion": "The submitted information in this premarket notification is complete and supports a substantial equivalence decision.",
        "classification": "Class II",
        "panel": "Clinical Chemistry (75)",
        "measurand": "Capillary whole blood glucose from the fingertip",
        "submission_number": "k143548",
        "intended_use": "The TRUE METRIX GO Self Monitoring Blood Glucose System is intended for the quantitative measurement of glucose (sugar) in fresh capillary whole blood samples drawn from the fingertip. The TRUE METRIX GO Self Monitoring Blood Glucose System is intended to be used by a single person and not shared. The TRUE METRIX GO Self Monitoring Blood Glucose System is intended for self-testing outside the body (in vitro diagnostic use) by people with diabetes at home as an aid to monitor the effectiveness of diabetes control. The TRUE METRIX GO Self Monitoring Blood Glucose System should not be used for the diagnosis or screening of diabetes or for neonate use.",
        "regulation_section": "21 CFR 862.1345, Glucose test system",
        "product_code": "NBW, System, Test, Blood Glucose, Over the Counter LFR, Glucose Dehydrogenase, Glucose",
        "comparison_with_predicate": "Similarities of the Blood Glucose System: Intended Use/Indications for Use: It is intended to be used for quantitative measurement of glucose in fresh capillary whole blood as an aid to monitor the effectiveness of diabetes control in people with diabetes. Detection method: Electrochemical Biosensor. Enzyme: FAD-Glucose Dehydrogenase. Calibration Coding: Auto coding. Differences of the Blood Glucose System: Memory: 480 test results vs 500 test results. Test range: 10 - 600 mg/dL vs 20-600 mg/dL. Sample sites: Fresh Capillary Whole Blood from the fingertip, forearm, palm, venous whole blood, arterial and neonate whole blood vs Fresh Capillary Whole Blood from the fingertip. Sample volume: 0.6 \u00b5L vs 0.5 \u00b5L. Hematocrit range: 0-70% vs 20-70%. Altitude Study: Up to 10,000 feet vs Up to 10,200 feet. Glucose measuring range: 10-600 mg/dL vs 20-600 mg/dL. Operating Temperature: 41-113 \u00b0F vs 40-86 \u00b0F. Operating Humidity: 10-93% RH vs 10-80% RH. Glucose Assay Time: 5 seconds vs 4-7 seconds."
    },
    "K163517.txt": {
        "applicant": "Liofilchem\u00ae s.r.l.",
        "conclusion": "The submitted information in this premarket notification is complete and supports a substantial equivalence decision.",
        "classification": "II",
        "panel": "83 \u2013 Microbiology",
        "measurand": "Telavancin 0.016 \u2013 256 \u00b5g/mL",
        "submission_number": "K163517",
        "intended_use": "The Liofilchem MIC Test Strip (MTS) is a quantitative method intended for the in vitro determination of antimicrobial susceptibility of non-fastidious Gram negative and Gram positive aerobic bacteria (for example, Enterobacteriaceae, Pseudomonas, Enterococcus and Staphylococcus species) and fastidious bacteria (for example, anaerobes, Haemophilus and Streptococcus species and N. gonorrhoeae). MTS consists of specialized paper impregnated with a pre-defined concentration gradient of an antimicrobial agent, which is used to determine the minimum inhibitory concentration (MIC) in \u03bcg/mL of antimicrobial agents against bacteria as tested on agar media using overnight incubation and manual reading procedures.",
        "regulation_section": "866.1640 Antimicrobial Susceptibility Test Powder",
        "product_code": "JWY \u2013 Manual Antimicrobial Test Systems",
        "comparison_with_predicate": "Similarities: Intended Use, Media, Inoculation, Reading, Result. Differences: Antibiotic, Incubation."
    },
    "K152495.txt": {
        "applicant": "Guangzhou Wondfo Biotech Co., Ltd.",
        "conclusion": "The submitted information in this premarket notification is complete and supports a substantial equivalence decision.",
        "classification": "Class II",
        "panel": "Toxicology, 91",
        "measurand": "Propoxyphene",
        "submission_number": "k152495",
        "intended_use": "The Wondfo Propoxyphene Urine Test is an immunochromatographic assay for the qualitative determination of d-Propoxyphene in human urine at a cutoff concentration of 300 ng/mL. The test is available in a dip card format and a test cup format. It is intended for prescription use and over the counter use.",
        "regulation_section": "21 CFR \u00a7862.3700",
        "product_code": "JXN",
        "comparison_with_predicate": "Similarities: Indications for Use, Methodology, Specimen Type, Cut-off value, Test format, Assay type. Differences: Special Conditions for Use - OTC and prescription use."
    },
    "K181324.txt": {
        "applicant": "BioFire Diagnostics, LLC",
        "conclusion": "The FilmArray Pneumonia Panel plus is substantially equivalent to the predicate device FilmArray Respiratory Panel 2 plus (RP2plus).",
        "classification": "Class II (Special Controls)",
        "panel": "83-Microbiology",
        "measurand": "Acinetobacter calcoaceticus-baumannii complex, Enterobacter cloacae complex, Escherichia coli, Haemophilus influenzae, Klebsiella aerogenes, Klebsiella oxytoca, Klebsiella pneumoniae group, Moraxella catarrhalis, Proteus spp., Pseudomonas aeruginosa, Serratia marcescens, Staphylococcus aureus, Streptococcus agalactiae, Streptococcus pneumoniae, Streptococcus pyogenes, Chlamydia pneumoniae, Legionella pneumophila, Mycoplasma pneumoniae, Adenovirus, Coronavirus, Human Metapneumovirus, Human Rhinovirus/Enterovirus, Influenza A, Influenza B, Middle East Respiratory Syndrome Coronavirus (MERS-CoV), Parainfluenza Virus, Respiratory Syncytial Virus, CTX-M, IMP, KPC, NDM, OXA-48-like, VIM, mecA/C and MREJ.",
        "submission_number": "K181324",
        "intended_use": "The FilmArray Pneumonia Panel plus is a multiplexed nucleic acid test intended for use with FilmArray, FilmArray 2.0, or FilmArray Torch systems for the simultaneous detection and identification of nucleic acids from Middle East Respiratory Syndrome Coronavirus (MERS-CoV) and multiple respiratory viral and bacterial nucleic acids, as well as select antimicrobial resistance genes, in sputum-like specimens (induced or expectorated sputum, or endotracheal aspirates) or bronchoalveolar lavage (BAL)-like specimens (BAL or mini-BAL) obtained from individuals meeting MERS-CoV clinical and/or epidemiological criteria.",
        "regulation_section": "21 CFR 866.4001 \u2013 MERS-CoV and common respiratory pathogens multiplex nucleic acid detection system",
        "product_code": "PZF",
        "comparison_with_predicate": "The FilmArray Pneumonia Panel plus is similar to the FilmArray Respiratory Panel 2 plus (RP2plus) in that both are multiplexed nucleic acid tests intended for the detection and identification of multiple respiratory viral and bacterial nucleic acids, as well as select antimicrobial resistance genes. However, the FilmArray Pneumonia Panel plus is used with sputum-like and BAL-like specimens, while the RP2plus is used with nasopharyngeal swabs."
    },
    "K162840.txt": {
        "applicant": "Roche Diagnostics",
        "conclusion": "The submitted information in this premarket notification is complete and supports a substantial equivalence decision.",
        "classification": "Class II",
        "panel": "Clinical Chemistry (75)",
        "measurand": "Total 25-hydroxyvitamin D (25-OH vitamin D)",
        "submission_number": "k162840",
        "intended_use": "The Elecsys Vitamin D total II assay is intended for the quantitative determination of total 25-hydroxyvitamin D in human serum and plasma. This assay is to be used as an aid in the assessment of vitamin D sufficiency in adults.",
        "regulation_section": "21 CFR 862.1825, Vitamin D Test System",
        "product_code": "MRG \u2013 Vitamin D Test System",
        "comparison_with_predicate": "A method comparison was performed using the candidate Elecsys Vitamin D total II assay and the predicate Elecsys Vitamin D Assay to assess the bias between the two assays. A total of 105 single native donors serum samples were measured in singleton on the cobas e 411 analyzer in one run covering the entire measuring range of the predicate device."
    },
    "K173887.txt": {
        "applicant": "Roche Molecular Systems, Inc.",
        "conclusion": "The submitted information in this premarket notification is complete and supports a substantial equivalence decision.",
        "classification": "Class II",
        "panel": "Microbiology (83)",
        "measurand": "Chlamydia trachomatis and Neisseria gonorrhoeae DNA",
        "submission_number": "K173887",
        "intended_use": "The cobas CT/NG on the cobas 6800/8800 system is an automated, qualitative in vitro nucleic acid diagnostic test, that utilizes real-time polymerase chain reaction (PCR), for the direct detection of Chlamydia trachomatis (CT) and/or Neisseria gonorrhoeae (NG) DNA in male and female urine, clinician-instructed self-collected vaginal swab specimens (collected in a clinical setting), clinician-collected vaginal swab specimens, and endocervical swab specimens, all collected in cobas PCR Media (Roche Molecular Systems, Inc.), and cervical specimens collected in PreservCyt solution. This test is intended as an aid in the diagnosis of chlamydial and gonococcal disease in both symptomatic and asymptomatic individuals.",
        "regulation_section": "21 CFR 866.3390 - Neisseria spp. direct serological test reagents",
        "product_code": "LSL - DNA-Reagents, Neisseria",
        "comparison_with_predicate": "Similarities: Regulation 866.3390, Intended Use: The cobas CT/NG on the cobas 6800/8800 system is an automated, qualitative in vitro nucleic acid diagnostic test, that utilizes real-time polymerase chain reaction (PCR), for the direct detection of Chlamydia trachomatis (CT) and/or Neisseria gonorrhoeae (NG) DNA in male and female urine, clinician instructed self-collected vaginal swab specimens (collected in a clinical setting), clinician-collected vaginal swab specimens, and endocervical swab specimens, all collected in cobas PCR Media (Roche Molecular Systems, Inc.), and cervical specimens collected in PreservCyt solution. This test is intended as an aid in the diagnosis of chlamydial and gonococcal disease in both symptomatic and asymptomatic individuals."
    },
    "K162895.txt": {
        "applicant": "Roche Diagnostics",
        "conclusion": "The submitted information in this premarket notification is complete and supports a substantial equivalence decision.",
        "classification": "Class II",
        "panel": "Chemistry",
        "measurand": "Cardiac troponin T (cTnT)",
        "submission_number": "K162895",
        "intended_use": "Immunoassay for the in vitro quantitative determination of cardiac troponin T (cTnT) in lithium heparin plasma. The immunoassay is intended to aid in the diagnosis of myocardial infarction.",
        "regulation_section": "21 CFR 862.1215 - Creatine phosphokinase/creatine kinase or isoenzymes test system",
        "product_code": "MMI",
        "comparison_with_predicate": "Similarities: Indications for use, Analyte, Type of immunoassay, Detection technology. Differences: Indications for use, Cut-off for the aid in the diagnosis of myocardial infarction, Type of specimen, Assay range."
    },
    "K180264.txt": {
        "applicant": "Gold Standard Diagnostics",
        "conclusion": "The submitted information in this premarket notification is complete and supports a substantial equivalence decision.",
        "classification": "Class II",
        "panel": "Microbiology",
        "measurand": "Anti-Borrelia burgdorferi (IgM and IgG) antibodies",
        "submission_number": "K180264",
        "intended_use": "The Gold Standard Diagnostics Borrelia burgdorferi IgG/IgM ELISA Test Kit is intended as a qualitative presumptive (first-step) test for the detection of IgG and IgM antibodies to B. burgdorferi sensu stricto in human serum from symptomatic patients or people suspected of infection. Positive and equivocal results must be supplemented by testing with a second-step Western blot assay.",
        "regulation_section": "21 CFR 866.3830; Treponema pallidum treponemal test reagents.",
        "product_code": "LSR; Reagent, Borrelia Serological Reagent",
        "comparison_with_predicate": "Similarities: Intended Use, Assay Format, Technology, Sample Matrix, Controls Provided, Reagents Provided, Reported Results, Interpretation. Differences: Sample Processing, Volumes, Incubation, Antigens, Results Interpretation."
    },
    "K160682.txt": {
        "applicant": "Ascensia Diabetes Care",
        "conclusion": "The submitted information in this premarket notification is complete and supports a substantial equivalence decision.",
        "classification": "Class II",
        "panel": "75, Clinical Chemistry",
        "measurand": "Glucose in fresh capillary whole blood from the fingertip and palm.",
        "submission_number": "k160682",
        "intended_use": "The Contour\u00ae Next ONE blood glucose monitoring system is intended to be used for the quantitative measurement of glucose in fresh capillary whole blood drawn from the fingertips or palm. The Contour\u00ae Next ONE blood glucose monitoring system is intended to be used by a single person and should not be shared. The Contour\u00ae Next ONE blood glucose monitoring system is intended for self-testing outside the body (in vitro diagnostic use) by people with diabetes at home as an aid in monitoring the effectiveness of a diabetes control program. The Contour\u00ae Next ONE blood glucose monitoring system should not be used for the diagnosis of or screening for diabetes or for neonatal use. Alternative site testing (palm) should be done only during steady state times (when glucose is not changing rapidly). The Contour\u00ae Next test strips are for use with the Contour\u00ae Next ONE blood glucose meter to quantitatively measure glucose in fresh capillary whole blood drawn from the fingertips or palm. The system is intended for in vitro diagnostic use only.",
        "regulation_section": "21 CFR 862.1345",
        "product_code": "NBW, Blood glucose test system, over the counter; LFR, Glucose Dehydrogenase, Glucose",
        "comparison_with_predicate": "Similarities: Intended Use, Test strip, Test Strip Chemistry, Measuring Range, Blood sample volume, Controls, Control solution ranges, Automatic calibration. Differences: Wireless technology, PC connection, Display, Battery type, Test memory, Sample re-application capability."
    },
    "K181092.txt": {
        "applicant": "bioM\u00e9rieux SA",
        "conclusion": "The submitted information in this premarket notification is complete and supports a substantial equivalence decision.",
        "classification": "Class II",
        "panel": "83: Microbiology",
        "measurand": "Colonies of carbapenemase-producing Escherichia coli and Klebsiella pneumoniae",
        "submission_number": "K181092",
        "intended_use": "CHROMID CARBA agar is a selective and differential chromogenic medium that is intended for the qualitative detection and presumptive identification of carbapenemase-producing Escherichia coli and Klebsiella pneumoniae in rectal swab specimens from patients at risk of colonization. CHROMID CARBA agar is intended as an aid in the detection, identification of colonization and control of these bacteria in a healthcare setting.",
        "regulation_section": "21 CFR 866.1700: Culture medium for antimicrobial susceptibility tests",
        "product_code": "JSO: Culture Media, Antimicrobial Susceptibility Test, Excluding Mueller Hinton Agar",
        "comparison_with_predicate": "Similarities: CHROMID CARBA agar is a selective and differential chromogenic medium that is intended for the qualitative detection and presumptive identification of carbapenemase-producing Escherichia coli and Klebsiella pneumoniae in rectal swab specimens from patients at risk of colonization. CHROMID CARBA agar is intended as an aid in the detection, identification of colonization and control of these bacteria in a healthcare setting. Rectal swabs are inoculated directly onto CHROMID CARBA agar without enrichment and results can be interpreted after incubation for 18-24 hours. Presumptive carbapenemase-producing colonies of E. coli appear pink to burgundy and those of K. pneumoniae appear blue-green or blue-grey. Differences: Specimen Type - Rectal swab; Target Species, Resistance Mechanisms and Associated Colony Colors - Carbapenemase-producing E. coli (pink-burgundy) and K. pneumoniae (blue-green/blue-grey); Incubation Time - 18-24 hours."
    },
    "K170464.txt": {
        "applicant": "Nova Biomedical Corporation",
        "conclusion": "The submitted information in this premarket notification is complete and supports a substantial equivalence decision.",
        "classification": "Class II",
        "panel": "Clinical Chemistry (75)",
        "measurand": "Fresh capillary whole blood glucose from the fingertip",
        "submission_number": "k170464",
        "intended_use": "The StatStrip Xpress Blood Glucose Monitoring System is intended to be used for the quantitative measurement of glucose in fresh capillary whole blood obtained from the fingertip. It is intended for single-patient home use and should not be shared. It is intended for self-testing outside the body by people with diabetes mellitus as an aid to monitor the effectiveness of diabetes control. It is not intended for the diagnosis of or screening for diabetes, and it is not intended for use with neonates.",
        "regulation_section": "21 CFR 862.1345, Glucose test system",
        "product_code": "NBW, System, Test, Blood Glucose, Over The Counter",
        "comparison_with_predicate": "Similarities: Intended Use/Indications for Use, Specimen type, Test Principle, Enzyme. Differences: Outer carton labeling, Test strip package insert."
    },
    "K150041.txt": {
        "applicant": "Coramed Technologies, LLC",
        "conclusion": "The submitted information in this premarket notification is complete and supports a substantial equivalence decision.",
        "classification": "Class II",
        "panel": "Hematology (81)",
        "measurand": "Coagulation factors (intrinsic and extrinsic pathway) and platelet aggregation",
        "submission_number": "K150041",
        "intended_use": "The CORA System is intended for in vitro diagnostic use to provide semi-quantitative indications of the hemostasis state of a blood sample. The CORA System records the kinetic changes in a venous sample of 3.2% citrated whole blood as the sample clots, and retracts in real time. The system output consists of a table of numerical values for parameters R, K, Angle, MA, and FLEV. The CORA System provides specific blood modifiers, in the form of reagents dried-in-place within CORA Cartridges. Results from the CORA analysis should not be the sole basis for a patient diagnosis, but should be evaluated together with the patient's medical history, the clinical picture and, if necessary, further hemostasis tests.",
        "regulation_section": "21 CFR 864.5425, Multipurpose system for in vitro coagulation studies; 21 CFR 864.5700, Automated platelet aggregation system",
        "product_code": "JPA, System, Multipurpose For In Vitro Coagulation Control; GGN, Plasma, Coagulation Control",
        "comparison_with_predicate": "The CORA System is intended for in vitro diagnostic use to provide semi-quantitative indications of the hemostasis state of a blood sample. The CORA System records the kinetic changes in a venous sample of 3.2% citrated whole blood as the sample clots, and retracts in real time. The system output consists of a table of numerical values for parameters R, K, Angle, MA, and FLEV. The CORA System provides specific blood modifiers, in the form of reagents dried-in-place within CORA Cartridges. Results from the CORA analysis should not be the sole basis for a patient diagnosis, but should be evaluated together with the patient's medical history, the clinical picture and, if necessary, further hemostasis tests. The TEG 5000 Series Analyzer is intended to be used to provide a quantitative and qualitative indication of the coagulation state of a blood sample by monitoring, measuring, analyzing and reporting coagulation parameter information. The Thrombelastograph (TEG) Coagulation Analyzer TEG-5000 Series records the kinetic changes in a sample of whole blood, plasma or platelet-rich-plasma as the sample clots, retracts and./or lyses (breaks apart). Results from the TEG Analyzer should not be the sole basis for a patient diagnosis; TEG results should be considered along with a clinical assessment on the patient's condition and other coagulation laboratory tests. For professional use only."
    },
    "K181043.txt": {
        "applicant": "Nova Biomedical Corporation",
        "conclusion": "The submitted information in this premarket notification is complete and supports a substantial equivalence decision.",
        "classification": "II",
        "panel": "Clinical Chemistry",
        "measurand": "Capillary whole blood glucose",
        "submission_number": "k181043",
        "intended_use": "The StatStrip Glucose Hospital Meter System is intended for point-of-care, in vitro diagnostic, multiple-patient use for the quantitative determination of glucose in capillary finger stick, venous whole blood, arterial whole blood, neonate arterial whole blood and neonate heel stick specimens throughout all hospital and all professional healthcare settings including patients receiving intensive medical intervention/therapy.",
        "regulation_section": "21 CFR 862.1345",
        "product_code": "PZI",
        "comparison_with_predicate": "Similarities and Differences"
    },
    "K161714.txt": {
        "applicant": "Immunalysis Corporation",
        "conclusion": "The submitted information in this premarket notification is complete and supports a substantial equivalence decision.",
        "classification": "Class II",
        "panel": "Toxicology (91)",
        "measurand": "Barbiturates",
        "submission_number": "k161714",
        "intended_use": "The Immunalysis Barbiturates Urine Enzyme Immunoassay is a homogeneous enzyme immunoassay with a cutoff of 200 ng/mL. The assay is intended for use in laboratories for the qualitative and semi-quantitative analysis of Barbiturates in human urine with automated clinical chemistry analyzers. This assay is calibrated against Secobarbital. This in vitro diagnostic device is for prescription use only.",
        "regulation_section": "21 CFR 862.3150 Barbiturate test system, 21 CFR 862.3200, Clinical toxicology calibrator",
        "product_code": "DIS, DKB",
        "comparison_with_predicate": "Similarities - Reagent: Intended Use, Assay cutoff, Calibrator compound, Assay type, Storage conditions. Differences - Reagent: Calibrators, Controls, Antibody type. Similarities - Calibrators: Calibrator drug. Differences - Calibrators: Calibrator Levels."
    },
    "K142965.txt": {
        "applicant": "Ventana Medical Systems, Inc.",
        "conclusion": "The submitted information in this premarket notification is complete and supports a substantial equivalence decision.",
        "classification": "Class II",
        "panel": "Pathology (88)",
        "measurand": "progesterone receptor (PR) protein",
        "submission_number": "k142965",
        "intended_use": "The VirtuosoTM system provides automated digital slide creation, management, analysis, and viewing. It is intended for in vitro diagnostic use as an aid to the pathologist in the display, detection, counting, review and classification of tissues and cells of clinical interest based on particular morphology, color, intensity, size, pattern and shape. The VirtuosoTM System for IHC PR (1E2) using the VENTANA iScan HT is for the digital read application. This particular Virtuoso system is intended for use as an aid to the pathologist in the qualitative detection of progesterone receptor (PR) protein in formalin-fixed, paraffin-embedded normal and neoplastic tissue. This device is an accessory to Ventana Medical Systems, Inc. CONFIRM\u2122 anti-Progesterone Receptor (PR) (1E2) Rabbit Monoclonal Primary Antibody assay. The CONFIRM\u2122 anti-Progesterone Receptor (PR) (1E2) Rabbit Monoclonal Primary Antibody assay is indicated for use as an aid in the assessment of breast cancer patients for whom endocrine treatment is being considered (but is not the sole basis for treatment).",
        "regulation_section": "21 CFR \u00a7864.1860, Immunohistochemistry reagents and kits",
        "product_code": "OEO - Automated Digital Image Manual Interpretation Microscope",
        "comparison_with_predicate": "Same"
    },
    "K181889.txt": {
        "applicant": "Liofilchem s.r.l.",
        "conclusion": "The submitted information in this premarket notification is complete and supports a substantial equivalence decision.",
        "classification": "II",
        "panel": "83 \u2013 Microbiology",
        "measurand": "Penicillin 0.002-32 \u03bcg/mL",
        "submission_number": "K181889",
        "intended_use": "The Liofilchem\u00ae MTS (MIC Test Strip) Penicillin 0.002-32 \u03bcg/mL is a quantitative method intended for the in vitro determination of antimicrobial susceptibility of bacteria.",
        "regulation_section": "866.1640 Antimicrobial Susceptibility Test Powder",
        "product_code": "JWY - Manual Antimicrobial Susceptibility Test Systems",
        "comparison_with_predicate": "Similarities: Intended Use, Inoculum, Reading, Result. Differences: Media, Antibiotic, Incubation."
    },
    "K181288.txt": {
        "applicant": "Athelas Inc.",
        "conclusion": "The submitted information in this premarket notification is complete and supports a substantial equivalence decision.",
        "classification": "Class II",
        "panel": "Hematology (81)",
        "measurand": "White blood cell count (WBC) and percent neutrophil count (NEUT%)",
        "submission_number": "K181288",
        "intended_use": "Athelas One is indicated for use for quantitative determination of white blood cells (WBC) and Neutrophil percentages (NEUT%) in capillary or K2EDTA venous whole blood. The Athelas One system is for In Vitro Diagnostic use only. The Athelas One is only to be used with Athelas One Test Strips. The Athelas One is indicated for use in clinical laboratories and for point of care settings. The Athelas One is only indicated for use in adult populations (aged 21 and older).",
        "regulation_section": "21 CFR 864.5220, Automated differential cell counter",
        "product_code": "GKZ, Counter, differential cell",
        "comparison_with_predicate": "Similarities: Intended Use, Intended Use Settings, Specimen Type, Parameters. Differences: Test Principle, Controls/Calibrators, Sample Processing, Sample Volume, Measurement Range, Calibration."
    },
    "K183462.txt": {
        "applicant": "MRIGlobal",
        "conclusion": "The submitted information in this premarket notification is complete and supports a substantial equivalence decision.",
        "classification": "Class II",
        "panel": "83- Microbiology",
        "measurand": "Nucleic acid sequences of Bacillus anthracis pX01 and pX02 plasmids",
        "submission_number": "K183462",
        "intended_use": "The Applied Biosystems Bacillus anthracis Detection Kit is a real-time polymerase chain reaction (PCR) test kit intended for the qualitative in vitro diagnostic (IVD) detection of target DNA sequences for Bacillus anthracis (B. anthracis, or BA). The Applied Biosystems Bacillus anthracis Detection Kit is intended to test human whole blood (EDTA) specimens and blood culture specimens with growth detected by a continuous monitoring blood culture system. Blood culture specimens must be determined to contain gram-positive bacilli by Gram stain prior to testing. Testing of whole blood specimens must be performed concomitantly with standard of care blood culture.",
        "regulation_section": "CFR 866.4000",
        "product_code": "QIF, OOI",
        "comparison_with_predicate": "Similarities: Intended Use, Methodology/Technological Principle, Specimen Types, Result Output, Test Interpretation. Differences: Multiplex Capability, Assay Targets, Sample Extraction, PCR Reagents, Instrumentation, Throughput, User Complexity End User."
    },
    "K180936.txt": {
        "applicant": "bioM\u00e9rieux, Inc.",
        "conclusion": "The submitted information in this premarket notification is complete and supports a substantial equivalence decision.",
        "classification": "II",
        "panel": "83 \u2013Microbiology",
        "measurand": "Telavancin 0.002 \u2013 32 \u00b5g/mL",
        "submission_number": "K180936",
        "intended_use": "ETEST is a quantitative technique for determination of antimicrobial susceptibility of non-fastidious Gram-negative and Gram-positive aerobic bacteria such as Enterobacteriaceae, Pseudomonas, Staphylococcus, and Enterococcus species and fastidious bacteria, such as anaerobes, N. gonorrhoeae, S. pneumoniae, Streptococcus and Haemophilus species. The system comprises a predefined antibiotic gradient which is used to determine the Minimum Inhibitory Concentration (MIC), in \u00b5g/mL, of different antimicrobial agents against microorganisms as tested on agar media using overnight incubation.",
        "regulation_section": "866.1640 Antimicrobial Susceptibility Test Powder",
        "product_code": "JWY \u2013 Manual Antimicrobial Test Systems",
        "comparison_with_predicate": "Similarities: Intended Use, Antimicrobial Concentration Range, Test Design, Inoculation, Result. Differences: Claimed organisms, Antimicrobial Agent, Incubation."
    },
    "K143329.txt": {
        "applicant": "Quidel Corporation",
        "conclusion": "The submitted information in this premarket notification is complete and supports a substantial equivalence decision.",
        "classification": "Class II",
        "panel": "83 - Microbiology",
        "measurand": "A conserved multi-copy sequence of Trichomonas vaginalis genomic DNA",
        "submission_number": "K143329",
        "intended_use": "The AmpliVue\u00ae Trichomonas Assay is an in vitro diagnostic test, uses isothermal amplification technology (helicase-dependent amplification, HDA) for the qualitative detection of Trichomonas vaginalis nucleic acids isolated from clinician-collected vaginal swab specimens obtained from symptomatic or asymptomatic females to aid in the diagnosis of trichomoniasis.",
        "regulation_section": "21 CFR 866.3860",
        "product_code": "OUY - Trichomonas vaginalis nucleic acid amplification test system",
        "comparison_with_predicate": "Similarities: Intended Use - The AmpliVue\u00ae Trichomonas Assay is an in vitro diagnostic test, uses isothermal amplification technology (helicase-dependent amplification, HDA) for the qualitative detection of Trichomonas vaginalis nucleic acids isolated from clinician-collected vaginal swab specimens obtained from symptomatic or asymptomatic females to aid in the diagnosis of trichomoniasis. Assay Results - Qualitative. Differences: Sample Types - Clinician-collected Vaginal Swabs. Target Sequence Detected - Repeated DNA fragment located in T. vaginalis genome. Amplification Technology - Helicase-dependent amplification (HDA). Self-Contained System - Assay after sample preparation. Detection Technique - Manual. Instrument - None."
    },
    "K181379.txt": {
        "applicant": "TechLab Inc.",
        "conclusion": "The submitted information in this premarket notification is complete and supports a substantial equivalence decision.",
        "classification": "Class I",
        "panel": "83-Microbiology",
        "measurand": "H. pylori antigen",
        "submission_number": "K181379",
        "intended_use": "The TECHLAB H. PYLORI QUIK CHEK test is a rapid membrane enzyme immunoassay for the qualitative detection of Helicobacter pylori specific antigen in a single use cassette. It is intended for use with human fecal specimens to aid in the diagnosis of H. pylori infection and to demonstrate loss of H. pylori antigen following treatment. The test can be used with unpreserved fecal specimens and fecal specimens preserved in transport media from patients suspected of H. pylori infection. Testing of patients to demonstrate loss of H. pylori antigen following treatment should be performed no sooner than 4 weeks after completion of the treatment regimen. Test results should be taken into consideration by the physician in conjunction with the patient history and symptoms.",
        "regulation_section": "21 CFR 866.3110 Campylobacter fetus serological reagents",
        "product_code": "LYR-\u2013 Campylobacter pylori",
        "comparison_with_predicate": "Similarities: Product Code - LYR, Intended Use - The TECHLAB H. PYLORI QUIK CHEK\u2122 test is a rapid membrane enzyme immunoassay for the qualitative detection of Helicobacter pylori specific antigen in a single use cassette. It is intended for use with human fecal specimens to aid in the diagnosis of H. pylori infection and to demonstrate loss of H. pylori antigen following treatment. The test can be used with unpreserved fecal specimens and fecal specimens preserved in transport media from patients suspected of H. pylori infection. Testing of patients to demonstrate loss of H. pylori antigen following treatment should be performed no sooner than 4 weeks after completion of the treatment regimen. Test results should be taken into consideration by the physician in conjunction with the patient history and symptoms. Measured analyte - Detection of H. pylori stool antigen, Target Population - Persons suspected of having H. pylori infection, Type of Test - Qualitative, Controls - Positive and negative control included in kit Internal Control line, Storage - Refrigerated (2\u00b0C \u2013 8\u00b0C), Reading Method - Manual/Visual. Differences: Specimen Type - Fecal Specimens in Cary-Blair and C&S Transport Media, Time to Result - 30 minutes, Technology - Enzyme Linked Immunoassay (ELISA), Antibody Format - Polyclonal/Polyclonal."
    },
    "K190219.txt": {
        "applicant": "DiaSorin",
        "conclusion": "The submitted information in this premarket notification is complete and supports a substantial equivalence decision.",
        "classification": "Class II",
        "panel": "MI - Microbiology",
        "measurand": "Varizella zoster virus DNA",
        "submission_number": "K190219",
        "intended_use": "The DiaSorin Molecular Simplexa VZV Direct assay is intended for use on the LIAISON MDX instrument for the qualitative detection of varicella-zoster virus (VZV) DNA in cerebrospinal fluid (CSF) from patients with signs and/or symptoms of meningitis and/or encephalitis. This test is intended as an aid in the diagnosis of VZV infections of the central nervous system (CNS).",
        "regulation_section": "21 CFR 866.3970",
        "product_code": "PLO",
        "comparison_with_predicate": "The DiaSorin Molecular Simplexa VZV Direct assay is intended for use on the LIAISON MDX instrument for the qualitative detection of varicella-zoster virus (VZV) DNA in cerebrospinal fluid (CSF) from patients with signs and/or symptoms of meningitis and/or encephalitis. This test is intended as an aid in the diagnosis of VZV infections of the central nervous system (CNS). Negative results do not preclude VZV infection and should not be used as the sole basis for treatment or other patient management decisions. The assay is not intended for use as a donor screening test. The assay is for professional use only."
    },
    "K151265.txt": {
        "applicant": "SD Biosensor Inc.",
        "conclusion": "The submitted information in this premarket notification is complete and supports a substantial equivalence decision.",
        "classification": "Class II",
        "panel": "Chemistry",
        "measurand": "Capillary whole blood glucose from fingertip, palm, forearm, or upper arm.",
        "submission_number": "K151265",
        "intended_use": "SD GlucoNFC Blood Glucose Monitoring System is intended to be used for the quantitative measurement of glucose (sugar) in fresh capillary whole blood from fingertip, palm, forearm or upper arm. SD GlucoNFC Blood Glucose Monitoring System is intended to be used by a single person and should not be shared. It is intended for self-testing outside the body (in vitro diagnostic use) by people with diabetes at home as an aid to monitor the effectiveness of diabetes control.",
        "regulation_section": "862.1345, Glucose Test System",
        "product_code": "NBW - System, Test, Blood Glucose, Over-the-Counter",
        "comparison_with_predicate": "Similarities: Monitoring glucose in fresh capillary whole blood samples drawn from the fingertip, palm, forearm, or upper arm by people with diabetes at home to be used as an aid to monitor the effectiveness of diabetes control. Differences: Hematocrit range 10-70% vs 10-60%, Operating Temperature 46-113\u00b0F (8-45\u00b0C) vs 50-113\u00b0F (10-45\u00b0C), Operating Humidity 10-90% RH vs 15-90% RH, Operating Altitude Up to 11,480 ft. vs Up to 11,351 ft., Sample volume 0.5 mL vs 0.3 mL."
    },
    "K181700.txt": {
        "applicant": "Hardy Diagnostics",
        "conclusion": "The submitted information in this premarket notification is complete and supports a substantial equivalence decision.",
        "classification": "Class II",
        "panel": "83, Microbiology",
        "measurand": "Plazomicin 30\u00b5g",
        "submission_number": "K181700",
        "intended_use": "HardyDisk AST Disks are used for semi-quantitative in vitro susceptibility testing by the agar diffusion test procedure (Kirby-Bauer) of rapidly growing and certain fastidious bacterial pathogens.",
        "regulation_section": "21 CFR 866.1620 Antimicrobial Susceptibility Test Disc",
        "product_code": "JTN",
        "comparison_with_predicate": "Similarities: Test Method, Methodology, Inoculum, Inoculation Method, Reading Method. Differences: Product Name, Antimicrobial Agent, Concentration."
    },
    "K171971.txt": {
        "applicant": "Lite-On Technology Corp.",
        "conclusion": "The submitted information in this premarket notification is complete and supports a substantial equivalence decision.",
        "classification": "Class II",
        "panel": "Clinical Chemistry (75)",
        "measurand": "Alkaline phosphate (ALP), Alanine aminotransferase (ALT), Aspartate aminotransferase (AST), Blood urea nitrogen (BUN) and Creatinine (CREA)",
        "submission_number": "k171971",
        "intended_use": "The Comprehensive Metabolic Panel is intended to be used for the quantitative determination of Alkaline Phosphate (ALP), Alanine Aminotransferase (ALP/GPT), Aspartate Aminotransferase (AST/GOT), Blood Urea Nitrogen (BUN) and Creatinine (CREA) in concentrations in lithium-heparinized venous whole blood, heparinized plasma, or serum in a clinical laboratory setting or point-of-care location.",
        "regulation_section": "862.1050",
        "product_code": "CJE",
        "comparison_with_predicate": "Quantitative determination of alkaline phosphate, alanine aminotransferase, aspartate aminotransferase, blood urea nitrogen and creatinine concentrations in lithium-heparinized venous whole blood, heparinized plasma, or serum in a clinical laboratory setting or point-of-care location."
    },
    "K173829.txt": {
        "applicant": "Wallac Oy, a subsidiary of PerkinElmer",
        "conclusion": "The submitted information in this premarket notification is complete and supports a substantial equivalence decision.",
        "classification": "II",
        "panel": "Chemistry (75)",
        "measurand": "Acid-\u03b2-glucocerebrosidase (ABG), acid-sphingomyelinase (ASM), acid-\u03b1-glucosidase (GAA), \u03b2-galactocerebrosidase (GALC), \u03b1-galactosidase A (GLA), \u03b1-L-iduronidase (IDUA)",
        "submission_number": "k173829",
        "intended_use": "The NeoLSD MSMS Kit is intended for the quantitative measurement of the activity of the enzymes acid-\u03b2-glucocerebrosidase (ABG), acid-sphingomyelinase (ASM), acid-\u03b1-glucosidase (GAA), \u03b2-galactocerebrosidase (GALC), \u03b1-galactosidase A (GLA), and \u03b1-L-iduronidase (IDUA) in dried blood spots (DBS) from newborn babies. The analysis of the enzymatic activity is intended as an aid in screening newborns for the following lysosomal storage disorders (LSD) respectively; Gaucher Disease, Niemann-Pick A/B Disease, Pompe Disease, Krabbe Disease, Fabry Disease, and mucopolysaccharidosis Type I (MPS I) Disease.",
        "regulation_section": "862.1488 Lysosomal storage disorder newborn screening test system",
        "product_code": "PQW, PQT, PQU, PQV, QCL, QCM",
        "comparison_with_predicate": "Similarities and Differences"
    },
    "K150168.txt": {
        "applicant": "Siemens Healthcare Diagnostics, Inc.",
        "conclusion": "The submitted information in this premarket notification is complete and supports a substantial equivalence decision.",
        "classification": "Class II",
        "panel": "Toxicology (91)",
        "measurand": "Tacrolimus",
        "submission_number": "k150168",
        "intended_use": "The Dimension Tacrolimus Flex\u00ae Reagent Cartridge (TAC) is an in vitro diagnostic test for the quantitative measurement of tacrolimus in human whole blood on the Dimension\u00ae clinical chemistry system. Measurements of tacrolimus are used as an aid in the management of tacrolimus therapy in renal and hepatic transplant patients.",
        "regulation_section": "21 CFR \u00a7862.1678, Tacrolimus Test System",
        "product_code": "MLM, JIT",
        "comparison_with_predicate": "The Dimension\u00ae TAC Flex\u00ae reagent cartridge is similar to the ARCHITECT Tacrolimus Assay (k070820) in intended use, assay type, sample type, and high sample dilution, but differs in instrument, sample pretreatment, measuring range, and cross reactivity profile."
    },
    "K173817.txt": {
        "applicant": "Liofilchem s.r.l.",
        "conclusion": "The submitted information in this premarket notification is complete and supports a substantial equivalence decision.",
        "classification": "Class II",
        "panel": "Microbiology (83)",
        "measurand": "Ceftazidime/avibactam 0.016/4 \u2013 256/4 \u00b5g/mL",
        "submission_number": "K173817",
        "intended_use": "The Liofilchem MIC Test Strip (MTS) is a quantitative method intended for the in vitro determination of antimicrobial susceptibility of bacteria. MTS consists of specialized paper impregnated with a pre-defined concentration gradient of an antimicrobial agent, which is used to determine the minimum inhibitory concentration (MIC) in \u03bcg/mL of antimicrobial agents against bacteria as tested on agar media using overnight incubation and manual reading procedures. The Ceftazidime-avibactam MTS at concentrations of 0.016/4-256/4 \u03bcg/mL should be interpreted at 16-20 hours of incubation.",
        "regulation_section": "21 CFR 866.1640 Antimicrobial Susceptibility Test Powder",
        "product_code": "JWY \u2013 Manual Antimicrobial Test Systems",
        "comparison_with_predicate": "Similarities: Intended Use, Media, Inoculum, Reading, Result. Differences: Antimicrobial Agent, Incubation."
    },
    "K150588.txt": {
        "applicant": "Vermillion, Inc.",
        "conclusion": "The submitted information in this premarket notification is complete and supports a substantial equivalence decision.",
        "classification": "Class II",
        "panel": "Immunology (82)",
        "measurand": "Score based on 5 serum analytes",
        "submission_number": "K150588",
        "intended_use": "The OVA1 Next Generation test is a qualitative serum test that combines the results of five immunoassays into a single numeric result. It is indicated for women who meet the following criteria: over age 18, ovarian adnexal mass present for which surgery is planned, and not yet referred to an oncologist. The OVA1 Next Generation test is an aid to further assess the likelihood that malignancy is present when the physician\u2019s independent clinical and radiological evaluation does not indicate malignancy. The test is not intended as a screening or stand-alone diagnostic assay.",
        "regulation_section": "21 CFR \u00a7866.6050, Ovarian adnexal mass assessment score test system",
        "product_code": "ONX, Serum, algorithm, ovarian cancer assessment test",
        "comparison_with_predicate": "Similarities: The OVA1 Next Generation test is a qualitative serum test that combines the results of five immunoassays into a single numeric result. It is indicated for women who meet the following criteria: over age 18, ovarian adnexal mass present for which surgery is planned, and not yet referred to an oncologist. The OVA1 Next Generation test is an aid to further assess the likelihood that malignancy is present when the physician\u2019s independent clinical and radiological evaluation does not indicate malignancy. The test is not intended as a screening or stand-alone diagnostic assay. Differences: Analytes - Roche Elecsys APO, CA 125, TRF, FSH, HE4; Equation used for test - One equation with one cut-off; Clinical cutoff - Pre-menopausal and Post-menopausal: OVA1 risk score < 5.0 Low probability for malignancy, OVA1 risk score \u2265 5.0 High probability for malignancy; Platform - Roche cobas e601 (CA125, FSH and HE4), Roche cobas c501 (APO and TRF)"
    },
    "K193024.txt": {
        "applicant": "Thermo Fisher Scientific",
        "conclusion": "The submitted information in this premarket notification is complete and supports a substantial equivalence decision.",
        "classification": "Class II",
        "panel": "MI - Microbiology",
        "measurand": "Lefamulin in the dilution range of 0.008 \u2013 16 \u03bcg/mL",
        "submission_number": "K193024",
        "intended_use": "The Sensititre 20 - 24 hour Haemophilus influenzae/Streptococcus pneumoniae MIC or Breakpoint Susceptibility System is an in vitro diagnostic product for clinical susceptibility testing of H. influenzae, Streptococcus pneumoniae, and Streptococcus spp.",
        "regulation_section": "21 CFR 866.1640 - Antimicrobial Susceptibility Test Powder",
        "product_code": "JWY, LRG, LTT",
        "comparison_with_predicate": "The Sensititre Haemophilus influenzae/Streptococcus pneumoniae plates are in vitro diagnostic products for clinical susceptibility testing of Haemophilus influenzae, Streptococcus pneumoniae, and Streptococcus species. Same"
    },
    "K141114.txt": {
        "applicant": "Bio-Rad Laboratories",
        "conclusion": "The submitted information in this premarket notification is complete and supports a substantial equivalence decision.",
        "classification": "II",
        "panel": "Chemistry (75)",
        "measurand": "25-hydroxyvitamin D [25(OH) Vitamin D]",
        "submission_number": "k141114",
        "intended_use": "The BioPlex 2200 25-OH Vitamin D kit is a flow competitive immunoassay intended for the quantitative determination of 25-hydroxyvitamin D in human serum. The BioPlex 2200 25-OH vitamin D assay is to be used to aid in the assessment of vitamin D sufficiency. The BioPlex 2200 25-OH Vitamin D kit is intended for use with the BioPlex 2200 System.",
        "regulation_section": "862.1825 Vitamin D Test System",
        "product_code": "MRG",
        "comparison_with_predicate": "The BioPlex 2200 25-OH Vitamin D Kit is similar to the EUROIMMUN 25-OH Vitamin D ELISA in intended use, assay type, test principle, antibody, signal detection, and unit of measure. Differences include assay technology, conjugate, solid phase, measuring range, sample matrix, sample size, open pack stability, reagent storage, sample handling, instrumentation, and measuring wavelength."
    },
    "K153683.txt": {
        "applicant": "Sandstone Diagnostics, Inc.",
        "conclusion": "The submitted information in this premarket notification is complete and supports a substantial equivalence decision.",
        "classification": "Class II",
        "panel": "Hematology (81)",
        "measurand": "Sperm concentration",
        "submission_number": "K153683",
        "intended_use": "The Trak\u00ae Male Fertility Testing System is intended for semi-quantitative assessment of sperm concentration at 15 million sperm per milliliter (M/mL) or below, between 15 and 55 M/mL, and above 55 M/mL. Sperm concentration is only one factor that could impact a man's fertility status and time to pregnancy. For complete assessment of male reproductive health, the user should consult a physician. For in vitro, over the counter home use.",
        "regulation_section": "21 CFR \u00a7 864.5220, Automated differential cell counter",
        "product_code": "GKZ \u2013 Counter, Differential Cell",
        "comparison_with_predicate": "Similarities: Intended Use, Test Locale, Sample Type, Measurand. Differences: Test Type, Test Reporting, Test Principle, Primary Cut-off Result, Additional Reference Point, Test Control Method."
    },
    "K161217.txt": {
        "applicant": "bioM\u00e9rieux, Inc.",
        "conclusion": "The submitted information in this premarket notification is complete and supports a substantial equivalence decision.",
        "classification": "Class II",
        "panel": "83 Microbiology",
        "measurand": "The VITEK 2 AST-Gram Negative card contains the following concentrations of Ceftriaxone: 0.12, 0.25, 1, 4 and 16\u03bcg/mL (equivalent standard method concentration by efficacy in \u00b5g/mL). The MIC result reporting range for the card is \u2264 0.25 - \u226564 \u00b5g/mL.",
        "submission_number": "K161217",
        "intended_use": "The VITEK\u00ae2 Antimicrobial Susceptibility Test (AST) is intended to be used with the VITEK\u00ae2 Systems for the automated quantitative or qualitative susceptibility testing of isolated colonies for the most clinically significant aerobic gram-negative bacilli, Staphylococcus spp., Enterococcus spp., Streptococcus spp., S. pneumoniae and clinically significant yeast.",
        "regulation_section": "21 CFR 866.1645 Fully Automated Short-Term Incubation Cycle Antimicrobial Susceptibility System",
        "product_code": "LON - Fully automated short-term incubation cycle antimicrobial susceptibility system LTW \u2013 Susceptibility Test Cards, Antimicrobial LTT \u2013 Panels, Test, Susceptibility, Antimicrobial",
        "comparison_with_predicate": "Similarities: Intended Use - Same, Test Method - Same, Inoculum - Same; Differences: Antimicrobial - Ceftriaxone, Antimicrobial Concentration - 0.12, 0.25, 1, 4 and 16, Reading Algorithm - Growth pattern analysis- Unique to Ceftriaxone"
    },
    "K182353.txt": {
        "applicant": "Phadia AB",
        "conclusion": "The submitted information in this premarket notification is complete and supports a substantial equivalence decision.",
        "classification": "Class II",
        "panel": "Immunology (82)",
        "measurand": "IgG autoantibodies specific to Centromere protein (CENP), U1 ribonucleoprotein (U1RNP), and ribonucleoprotein 70kDa (RNP70)",
        "submission_number": "K182353",
        "intended_use": "EliA CENP is intended for the in vitro semi-quantitative measurement of IgG antibodies directed to CENP in human serum and plasma (Li-heparin, EDTA) as an aid in the clinical diagnosis of scleroderma (CREST Syndrome) in conjunction with other laboratory and clinical findings. EliA CENP uses the EliA IgG method on the instrument Phadia 2500/5000. EliA U1RNP is intended for the in vitro semi-quantitative measurement of IgG antibodies directed to U1RNP in human serum and plasma (Li-heparin, EDTA) as an aid in the clinical diagnosis of mixed connective tissue disease (MCTD) and systemic lupus erythematosus (SLE) in conjunction with other laboratory and clinical findings. EliA U1RNP uses the EliA IgG method on the instrument Phadia 2500/5000. EliA RNP70 is intended for the in vitro semi-quantitative measurement of IgG antibodies directed to RNP70 in human serum and plasma (Li-heparin, EDTA) as an aid in the clinical diagnosis of mixed connective tissue disease (MCTD) and systemic lupus erythematosus (SLE) in conjunction with other laboratory and clinical findings. EliA RNP70 uses the EliA IgG method on the instrument Phadia 2500/5000.",
        "regulation_section": "21 CFR 866.5100, Antinuclear antibody immunological test system",
        "product_code": "LJM, Antinuclear Antibody (Enzyme-labeled), Antigen, Controls LKO, Anti-RNP Antibody, Antigen and Control",
        "comparison_with_predicate": "Similarities: Intended Use/Indications for Use EliA CENP is intended for the in vitro semi-quantitative measurement of IgG antibodies directed to CENP in human serum and plasma (heparin, EDTA, citrate) as an aid in the clinical diagnosis of scleroderma (CREST Syndrome) in conjunction with other laboratory and clinical findings. EliA CENP uses the EliA IgG method on the instrument ImmunoCAP 250. EliA CENP is intended for the in vitro semi-quantitative measurement of IgG antibodies directed to CENP in human serum and plasma (Li-heparin, EDTA) as an aid in the clinical diagnosis of scleroderma (CREST Syndrome) in conjunction with other laboratory and clinical findings. EliA CENP uses the EliA IgG method on the instrument Phadia 2500/5000. Intended Use/Indications for Use EliA U1RNP is intended for the in vitro semi-quantitative measurement of IgG antibodies directed to U1RNP in human serum and plasma (heparin, EDTA, citrate) as an aid in the clinical diagnosis of mixed connective tissue disease (MCTD) and systemic lupus erythematosus (SLE) in conjunction with other laboratory and clinical findings. EliA U1RNP uses the EliA IgG method on the instrument ImmunoCAP 250. EliA U1RNP is intended for the in vitro semi-quantitative measurement of IgG antibodies directed to U1RNP in human serum and plasma (Li-heparin, EDTA) as an aid in the clinical diagnosis of mixed connective tissue disease (MCTD) and systemic lupus erythematosus (SLE) in conjunction with other laboratory and clinical findings. EliA U1RNP uses the EliA IgG method on the instrument Phadia 2500/5000. Intended Use/Indications for Use EliA RNP70 is intended for the in vitro semi-quantitative measurement of IgG antibodies directed to RNP70 in human serum and plasma (heparin, EDTA) as an aid in the clinical diagnosis of mixed connective tissue disease (MCTD) and systemic lupus erythematosus (SLE) in conjunction with other laboratory and clinical findings. EliA RNP70 is to be used together with the EliA IgG method on the instrument ImmunoCAP 250. EliA RNP70 is intended for the in vitro semi-quantitative measurement of IgG antibodies directed to RNP70 in human serum and plasma (Li-heparin, EDTA) as an aid in the clinical diagnosis of mixed connective tissue disease (MCTD) and systemic lupus erythematosus (SLE) in conjunction with other laboratory and clinical findings. EliA RNP70 uses the EliA IgG method on the instrument Phadia 2500/5000."
    },
    "K162333.txt": {
        "applicant": "Guangzhou Wondfo Biotech Co., Ltd.",
        "conclusion": "The submitted information in this premarket notification is complete and supports a substantial equivalence decision.",
        "classification": "Class II",
        "panel": "Hematology (81)",
        "measurand": "Human hemoglobin (hHb) in feces",
        "submission_number": "K162333",
        "intended_use": "Wondfo One Step Fecal Occult Blood Test is a rapid test for the qualitative detection of human occult blood in feces. It is used as an aid in the diagnosis of gastrointestinal (GI) bleeding. The device is suitable for use in laboratories and physician\u2019s offices as well as for over the counter use. For in vitro diagnostic use only. For prescription use and over the counter use.",
        "regulation_section": "21 CFR 864.6550, Occult blood test",
        "product_code": "KHE, Reagent, Occult Blood",
        "comparison_with_predicate": "Statistical analysis of site-wise test results as well as combined results showed that Wondfo One Step FOB Test results have acceptable overall percent agreement as well as positive percent agreement and negative percent agreement with Orient Gene Biotech One Step Rapid FOB test results."
    },
    "K180607.txt": {
        "applicant": "KRONUS Market Development Associates, INC.",
        "conclusion": "The submitted information in this premarket notification is complete and supports a substantial equivalence decision.",
        "classification": "Class II",
        "panel": "Immunology (82)",
        "measurand": "Steroid 21-Hydroxylase Antibody (21-OHAb)",
        "submission_number": "K180607",
        "intended_use": "The KRONUS Steroid 21-Hydroxylase Autoantibody (21-OHAb) ELISA Kit is for the qualitative determination of antibodies to steroid 21-hydroxylase (21-OH) in human serum. The Steroid 21-Hydroxylase Autoantibody (21-OHAb) ELISA Kit is useful as an aid in the diagnosis of autoimmune adrenal disease, whether expressed as autoimmune Addison's disease (isolated) or Addison's disease as part of the more complex autoimmune polyglandular syndrome (APS), type I or II. The assay result is to be used in conjunction with other clinical and laboratory findings and is not a substitute for functional testing required to diagnose adrenal insufficiency.",
        "regulation_section": "21 CFR \u00a7 866.5660, Multiple autoantibody immunological test system",
        "product_code": "PCG, 21-Hydroxylase Antibody (21-OHAb) antibody assay",
        "comparison_with_predicate": "Similarities: Intended Use, Analyte, Sample Matrix, Incubation time. Differences: Methodology, Method/Principle, Assay format, Detection Equipment, Cut-off."
    },
    "K173202.txt": {
        "applicant": "Sekisui Medical Co., LTD",
        "conclusion": "The submitted information in this premarket notification is complete and supports a substantial equivalence decision.",
        "classification": "Class II",
        "panel": "Hematology (81)",
        "measurand": "Antithrombin activity (%)",
        "submission_number": "K173202",
        "intended_use": "CP3000 Coagulation Analyzer The CP3000 is a fully automated, random-access in vitro blood coagulation analyzer intended for use by healthcare professionals in the clinical laboratory. The CP3000 analyzer is designed to process plasma samples photometrically using chromogenic assays.",
        "regulation_section": "21 CFR 864.5425, Multipurpose system for in vitro coagulation studies",
        "product_code": "JPA",
        "comparison_with_predicate": "The CP3000 is a fully automated, random-access in vitro blood coagulation analyzer intended for use by healthcare professionals in the clinical laboratory. The CP3000 analyzer is designed to process plasma samples photometrically using chromogenic assays. The ACL TOP is a bench top, fully automated, random access analyzer designed specifically for in vitro diagnostic clinical use in the hemostasis laboratory for coagulation and/or fibrinolysis testing in the assessment of thrombosis and/or hemostasis. The system provides results for both direct hemostasis measurement and calculated parameters."
    },
    "K163260.txt": {
        "applicant": "Immunexpress, Inc.",
        "conclusion": "The submitted information in this premarket notification is complete and supports a substantial equivalence decision.",
        "classification": "Class II (Special Controls)",
        "panel": "83: Microbiology",
        "measurand": "Four mRNA transcript immune biomarkers: LAMP1, CEACAM4, PLA2G7, PLAC8",
        "submission_number": "K163260",
        "intended_use": "The SeptiCyte LAB is a gene expression assay using reverse transcription polymerase chain reaction to quantify the relative expression levels of host response genes isolated from whole blood collected in the PAXgene Blood RNA Tube. The SeptiCyte LAB is used in conjunction with clinical assessments and other laboratory findings as an aid to differentiate infection-positive (sepsis) from infection-negative systemic inflammation in patients suspected of sepsis on their first day of ICU admission. The SeptiCyte LAB generates a score (SeptiSCORE) that falls within one of four discrete Interpretation Bands based on the increasing likelihood of infection-positive systemic inflammation. The SeptiCyte LAB is intended for in-vitro diagnostic use.",
        "regulation_section": "21 CFR 866.3215; Device to detect and measure non-microbial analyte(s) in human clinical specimens to aid in assessment of patients with suspected sepsis",
        "product_code": "PRE",
        "comparison_with_predicate": "The SeptiCyte LAB is a gene expression assay using reverse transcription polymerase chain reaction to quantify the relative expression levels of host response genes isolated from whole blood collected in the PAXgene Blood RNA Tube. The SeptiCyte LAB is used in conjunction with clinical assessments and other laboratory findings as an aid to differentiate infection-positive (sepsis) from infection-negative systemic inflammation in patients suspected of sepsis on their first day of ICU admission. The SeptiCyte LAB generates a score (SeptiSCORE) that falls within one of four discrete Interpretation Bands based on the increasing likelihood of infection-positive systemic inflammation. The SeptiCyte LAB is intended for in-vitro diagnostic use. The B\u00b7R\u00b7A\u00b7H\u00b7M\u00b7S PCT sensitive KRYPTOR is an immunofluorescent assay using Time-Resolved Amplified Cryptate Emission (TRACE) technology to determine the concentration of PCT (procalcitonin) in human serum and EDTA or heparin plasma. The B\u00b7R\u00b7A\u00b7H\u00b7M\u00b7S PCT sensitive KRYPTOR is intended to be performed on the B\u00b7R\u00b7A\u00b7H\u00b7M\u00b7S KRYPTOR analyzer family. The B\u00b7R\u00b7A\u00b7H\u00b7M\u00b7S PCT sensitive KRYPTOR is intended for use in conjunction with other laboratory findings and clinical assessments to aid in the risk assessment of critically ill patients on their first day of Intensive Care Unit (ICU) admission for progression to severe sepsis and septic shock. The B\u00b7R\u00b7A\u00b7H\u00b7M\u00b7S PCT sensitive KRYPTOR is also intended for use to determine the change in PCT level over time as an aid in assessing the cumulative 28-day risk of all-cause mortality in conjunction with other laboratory findings and clinical assessments for patients diagnosed with severe sepsis or septic shock in the ICU or when obtained in the emergency department or other medical wards prior to ICU admission."
    },
    "K141689.txt": {
        "applicant": "Qualigen, Inc.",
        "conclusion": "The submitted information in this premarket notification is complete and supports a substantial equivalence decision.",
        "classification": "Class II",
        "panel": "Clinical Chemistry",
        "measurand": "C-reactive protein (CRP)",
        "submission_number": "k141689",
        "intended_use": "FastPack High Sensitivity C-Reactive Protein Immunoassay is to be used for evaluation of conditions thought to be associated with inflammation, in otherwise healthy individuals. The FastPack High Sensitivity C-Reactive Protein Immunoassay is intended for use with the FastPack Analyzer. Not intended for Point-of-Care use.",
        "regulation_section": "21 CFR 866.5270 \u2013 C-reactive protein immunological test system",
        "product_code": "DCK \u2013 C-reactive, protein, Antigen, Antiserum",
        "comparison_with_predicate": "Similarities and Differences between FastPack and Olympus hsCRP Assays"
    },
    "K182513.txt": {
        "applicant": "InDevR, Inc.",
        "conclusion": "The FluChip-8G Influenza A+B Assay is substantially equivalent to the CDC Human Influenza Virus Real-Time PCR Diagnostic Panel.",
        "classification": "Class II",
        "panel": "Microbiology (83)",
        "measurand": "Influenza A and influenza B viral nucleic acids.",
        "submission_number": "K182513",
        "intended_use": "The FluChip-8G Influenza A+B Assay is a multiplex RT-PCR in vitro diagnostic test intended for the qualitative detection and differentiation of seasonal influenza A/H3N2, seasonal influenza A/H1N1pdm09, and 'non-seasonal' influenza A subtypes other than seasonal H1N1pdm09 or H3N2. The assay is also intended for the qualitative detection and differentiation of the genetic lineage of human influenza B viruses as B/Victoria or B/Yamagata.",
        "regulation_section": "21 CFR 866.3980, Respiratory viral panel multiplex nucleic acid assay",
        "product_code": "OZE - Influenza A and influenza B multiplex nucleic acid assay (Primary)",
        "comparison_with_predicate": "The FluChip-8G Influenza A+B Assay (K182513) is similar to the CDC Human Influenza Virus Real-Time PCR Diagnostic Panel (K172091) in that both detect influenza A and B viruses, but the FluChip-8G assay also differentiates 'non-seasonal' influenza A subtypes."
    },
    "K161258.txt": {
        "applicant": "Inova Diagnostics, Inc.",
        "conclusion": "The submitted information in this premarket notification is complete and supports a substantial equivalence decision.",
        "classification": "Class II",
        "panel": "Immunology (82)",
        "measurand": "Anti-Neutrophil Cytoplasmic Antibodies (ANCA)",
        "submission_number": "K161258",
        "intended_use": "NOVA Lite DAPI ANCA (Ethanol) Kit is an indirect immunofluorescence assay for the qualitative detection and semi-quantitative determination of anti-neutrophil cytoplasmic antibodies (ANCA) of IgG isotypes in human serum by manual fluorescence microscopy or with NOVA View Automated Fluorescence Microscope. The presence of ANCA, in conjunction with other serological, radiological, histological, and clinical findings, aids in the diagnosis of ANCA associated vasculitides. A trained operator must confirm results when generated with the NOVA View device. NOVA Lite DAPI ANCA (Formalin) Kit is an indirect immunofluorescence assay for the qualitative detection and semi-quantitative determination of anti-neutrophil cytoplasmic antibodies (ANCA) of IgG istoypes in human serum by manual fluorescence microscopy or with NOVA View Automated Fluorescence Microscope. The presence of ANCA, in conjunction with other serological, radiological, histological, and clinical findings aids in the diagnosis of ANCA associated vasculitides. A trained operator must confirm results when generated with the NOVA View device. ANCA Formalin test is not intended to be used by itself, but in conjunction with ANCA Ethanol test.",
        "regulation_section": "21 CFR \u00a7866.5660, Multiple autoantibodies immunological test system",
        "product_code": "MOB, Aneutrophil cytoplasmic antibodies (ANCA)",
        "comparison_with_predicate": "Similarities: Intended use, Reported Result, Analyte, Methodology, Manual Interpretation, Antigen, Sample Matrix, Slides, Sample dilution, Conjugate, Controls, Storage, Shelf life. Differences: Automated Interpretation, Additional dye in Conjugate."
    },
    "K161619.txt": {
        "applicant": "Cepheid",
        "conclusion": "The submitted information in this premarket notification is complete and supports a substantial equivalence decision.",
        "classification": "Class II",
        "panel": "Microbiology (83)",
        "measurand": "Trichomonas vaginalis (TV) DNA",
        "submission_number": "K161619",
        "intended_use": "The Cepheid Xpert TV Assay, performed on the GeneXpert\u00ae Instrument Systems, is a qualitative in vitro diagnostic test for the detection of Trichomonas vaginalis genomic DNA. The test utilizes automated real-time polymerase chain reaction (PCR) to detect Trichomonas vaginalis genomic DNA. The Xpert TV Assay uses female and male urine specimens, endocervical swab specimens, and patient-collected vaginal swab specimens (collected in a clinical setting). The Xpert TV Assay is intended to aid in the diagnosis of trichomoniasis in symptomatic or asymptomatic individuals.",
        "regulation_section": "21 CFR 866.3860, Trichomonas vaginalis nucleic acid assay",
        "product_code": "OUY- Trichomonas vaginalis nucleic acid amplification test, OOI- Real time nucleic acid amplification system",
        "comparison_with_predicate": "Similarities: Intended Use, Assay Targets, Nucleic Acid Extraction, Assay Results, Collection Kit, Technology/Detection, Instrument System, Laboratory Users, Early Assay Termination function. Differences: Specimen Types, Urine Collection Kit."
    },
    "K150526.txt": {
        "applicant": "The Binding Site Group, Ltd.",
        "conclusion": "The submitted information in this premarket notification is complete and supports a substantial equivalence decision.",
        "classification": "Class II",
        "panel": "Immunology (82)",
        "measurand": "IgG4 subclass Antibody",
        "submission_number": "k150526",
        "intended_use": "The Optilite IgG4 kit is intended for the quantitative in vitro measurement of IgG4 in serum using the Binding Site Optilite analyser. Measurement of this immunoglobulin is an aid in the diagnosis of abnormal protein metabolism and the body's lack of ability to resist infectious agents. The test result should be used in conjunction with other laboratory and clinical findings.",
        "regulation_section": "21 CFR \u00a7866.5510 - Immunoglobulins A, G, M, D, E Immunological Test System",
        "product_code": "CFN - Method, Nephelometric, Immunoglobulins (G, A, M)",
        "comparison_with_predicate": "Passing-Bablok regression analysis generated the following result: y = 0.91x + 8.09 (mg/L) with correlation coefficient r = 0.999."
    },
    "K171974.txt": {
        "applicant": "Quidel Corporation",
        "conclusion": "The submitted information in this premarket notification is complete and supports a substantial equivalence decision.",
        "classification": "Class II",
        "panel": "Microbiology (83)",
        "measurand": "RSV RNA: Matrix Gene, hMPV RNA: Fusion Protein Gene",
        "submission_number": "K171974",
        "intended_use": "The Solana RSV+hMPV Assay is a qualitative in vitro diagnostic test for the detection and differentiation of RSV and hMPV viral RNA in nasal and nasopharyngeal swabs from patients with signs and symptoms of respiratory infection. This test is intended for use as an aid in the differential diagnosis of RSV and hMPV viral infections in humans in conjunction with clinical and epidemiological risk factors. This test is not intended to differentiate the two subtypes of RSV or the four genetic sub-lineages of hMPV. Negative results do not preclude RSV infection and/or hMPV infection and should not be used as the sole basis for diagnosis, treatment or other patient management decisions. Conversely, positive results do not rule-out bacterial infection or co-infection with other viruses. The agent detected may not be the definite cause of disease. The use of additional laboratory testing and clinical presentation must be considered in order to obtain the final diagnosis of respiratory viral infection.",
        "regulation_section": "21 CFR 866.3980 Respiratory viral panel multiplex nucleic acid assay",
        "product_code": "OCC, OEM, OOI",
        "comparison_with_predicate": "The Solana RSV+hMPV Assay is a qualitative in vitro diagnostic test for the detection and differentiation of RSV and hMPV viral RNA in nasal and nasopharyngeal swabs from patients with signs and symptoms of respiratory infection. This test is intended for use as an aid in the differential diagnosis of RSV and hMPV viral infections in humans in conjunction with clinical and epidemiological risk factors. This test is not intended to differentiate the two subtypes of RSV or the four genetic sub-lineages of hMPV. Negative results do not preclude RSV infection and/or hMPV infection and should not be used as the sole basis for diagnosis, treatment or other patient management decisions. Conversely, positive results do not rule-out bacterial infection or co-infection with other viruses. The agent detected may not be the definite cause of disease. The use of additional laboratory testing and clinical presentation must be considered in order to obtain the final diagnosis of respiratory viral infection."
    },
    "K160585.txt": {
        "applicant": "Streck, Inc.",
        "conclusion": "The submitted information in this premarket notification is complete and supports a substantial equivalence decision.",
        "classification": "Class II",
        "panel": "Hematology (81)",
        "measurand": "Assayed hematology parameters: WBC (103/\u03bcL), RBC (106/\u03bcL), HGB (g/dL), HCT (%), PLT (103/\u03bcL), and RET (%)",
        "submission_number": "K160585",
        "intended_use": "XN CAL is used for the calibration and calibration verification of Sysmex XN series (XN-10, XN-11, XN-20, XN-21, XN-L) analyzers. Assayed parameters include: WBC (103/\u03bcL), RBC (106/\u03bcL), HGB (g/dL), HCT (%), PLT (103/\u03bcL), and RET (%).",
        "regulation_section": "21 CFR \u00a7 864.8150, Calibrator for cell indices",
        "product_code": "KRX, Calibrator for cell indices",
        "comparison_with_predicate": "XN CAL is used for the calibration and calibration verification of the following Sysmex XN series hematology analyzers: XN-10, XN-11, XN-20, XN-21, and XN-L. XN CAL predicate is NOT cleared for calibration and calibration verification of XN-L analyzers."
    },
    "K180209.txt": {
        "applicant": "Diazyme Laboratories Inc.",
        "conclusion": "The submitted information in this premarket notification is complete and supports a substantial equivalence decision.",
        "classification": "Class II",
        "panel": "Hematology (81)",
        "measurand": "1,5-Anhydroglucitol (1,5-AG)",
        "submission_number": "k180209",
        "intended_use": "Diazyme 1,5-anhydroglucitol (1,5-AG) Assay is an enzymatic method intended for the quantitative determination of 1,5-anhydroglucitol (1,5-AG) in serum or plasma. The 1,5-AG Assay is for the intermediate term (preceding 1-2 weeks) monitoring of glycemic control in people with diabetes. For in vitro diagnostic use only.",
        "regulation_section": "21 CFR 864.7470; Glycosylated hemoglobin assay",
        "product_code": "NOZ; Assay, 1,5-Anhydroglucitol",
        "comparison_with_predicate": "Similarities/Differences Item Diazyme 1,5-AG Assay GlycoMark\u2122 (K031604) Indications for use The intermediate term monitoring of glycemic control in people with diabetes Sample Serum or plasma Same Test principle Pyranose oxidase (PROD) Same Linearity 0.5-110 ug/mL Same Methodology Colorimetric Same Instruments Beckman AU680 Roche Hitachi 917"
    },
    "K143502.txt": {
        "applicant": "Immunalysis Corporation",
        "conclusion": "The submitted information in this premarket notification is complete and supports a substantial equivalence decision.",
        "classification": "II",
        "panel": "91 \u2013 Toxicology",
        "measurand": "Opiates",
        "submission_number": "k143502",
        "intended_use": "The Immunalysis Opiates Urine Enzyme Immunoassay is a homogeneous enzyme immunoassay with a dual cutoff of 300ng/mL and 2000ng/mL. The assay is intended for use in laboratories for the qualitative and semi-quantitative analysis of opiates in human urine with automated clinical chemistry analyzers. This assay is calibrated against Morphine. This in-vitro diagnostic device is for prescription use only.",
        "regulation_section": "862.3650",
        "product_code": "DJG \u2013 Opiate Test System",
        "comparison_with_predicate": "Opiates Assay Item Immunalysis Opiates Urine EIA DAU Opiate Assay k011150 Intended Use For the qualitative and semi-quantitative determination of the presence of opiates in human urine at a cutoff of 300 ng/mL and 2000 ng/mL Same Type of Product Analytical Reagents Same Measured Analytes Opiates Same Test Matrix Urine Same Cutoff Levels 300 ng/mL and 2000 ng/mL of Morphine Same Test System Homogeneous Enzyme Immunoassay (EIA) Same Materials Antibody/Substrate Reagents and Enzyme Labeled Conjugate Same Mass Spectroscopy Confirmation Required for preliminary positive analytical results Same Antibody Monoclonal antibody to Opiates Same Storage 2-8\u00b0C until expiration date Same"
    },
    "K163626.txt": {
        "applicant": "Luminex Corporation",
        "conclusion": "The submitted information in this premarket notification is complete and supports a substantial equivalence decision.",
        "classification": "Class II",
        "panel": "Microbiology (83)",
        "measurand": "Bordetella pertussis toxin promoter, Bordetella parapertussis IS1001 insertion element in respective genomes.",
        "submission_number": "K163626",
        "intended_use": "The ARIES Bordetella Assay is a real-time polymerase chain reaction (PCR) based qualitative in vitro diagnostic test for the direct detection and identification of Bordetella pertussis (B. pertussis) and Bordetella parapertussis (B. parapertussis) nucleic acid in nasopharyngeal swab (NPS) specimens obtained from individuals suspected of having a respiratory tract infection attributable to B. pertussis or B. parapertussis.",
        "regulation_section": "866.3980",
        "product_code": "OZZ",
        "comparison_with_predicate": "The ARIES Bordetella Assay is a real-time polymerase chain reaction (PCR) based qualitative in vitro diagnostic test for the direct detection and identification of Bordetella pertussis (B. pertussis) and Bordetella parapertussis (B. parapertussis) nucleic acid in nasopharyngeal swab (NPS) specimens obtained from individuals suspected of having a respiratory tract infection attributable to B. pertussis or B. parapertussis. The illumigene Pertussis DNA Amplification Assay, performed on the illumipro-10\u2122, is a qualitative in vitro diagnostic test for the direct detection of Bordetella pertussis in human nasopharyngeal swab samples taken from patients suspected of having respiratory tract infection attributable to Bordetella pertussis."
    },
    "K173505.txt": {
        "applicant": "ForaCare Inc.",
        "conclusion": "The submitted information in this premarket notification is complete and supports a substantial equivalence decision.",
        "classification": "Class II",
        "panel": "Clinical Chemistry (75)",
        "measurand": "Capillary whole blood glucose from the fingertip",
        "submission_number": "K173505",
        "intended_use": "The FORA GTel Blood Glucose Monitoring System is intended for use in the quantitative measurement of glucose in fresh capillary whole blood drawn from the finger. It is intended for in vitro diagnostic use by people with diabetes mellitus at home as an aid in monitoring the effectiveness of diabetes control program. It is not intended for the diagnosis of or screening for diabetes mellitus, and is not intended for use on neonates. It is intended to be used by a single person and should not be shared.",
        "regulation_section": "21 CFR 862.1345, Glucose test system",
        "product_code": "NBW, System Test, Blood Glucose, Over the Counter",
        "comparison_with_predicate": "Similarities: Intended Use - Intended for the quantitative measurement of glucose as an aid in monitoring the effectiveness of a diabetes control program. Methodology - Glucose Dehydrogenase. Patient-Use - Single-patient use. Intended Use Population - Over-the-counter. Sample Type - Capillary whole blood samples drawn from fingertips. Measurement range - 20-600 mg/dL. Differences: Alternative Sites - No. Talking function - Yes. Data transmission - 3G."
    },
    "K182357.txt": {
        "applicant": "Hardy Diagnostics",
        "conclusion": "The submitted information in this premarket notification is complete and supports a substantial equivalence decision.",
        "classification": "Class II",
        "panel": "83, Microbiology",
        "measurand": "Eravacycline 20\u00b5g",
        "submission_number": "K182357",
        "intended_use": "HardyDisk AST Disks are used for semi-quantitative in vitro susceptibility testing by the agar diffusion test procedure (Kirby-Bauer) of rapidly growing and certain fastidious bacterial pathogens.",
        "regulation_section": "21 CFR 866.1620 Antimicrobial Susceptibility Test Disc",
        "product_code": "JTN",
        "comparison_with_predicate": "Similarities: Test Method, Methodology, Inoculum, Inoculation Method, Reading Method. Differences: Product Name, Antimicrobial Agent, Concentration."
    },
    "K143075.txt": {
        "applicant": "Tosoh Bioscience",
        "conclusion": "The submitted information in this premarket notification is complete and supports a substantial equivalence decision.",
        "classification": "Class I, reserved",
        "panel": "Clinical Chemistry (75)",
        "measurand": "Sex Hormone Binding Globulin (SHBG)",
        "submission_number": "k143075",
        "intended_use": "ST AIA-PACK SHBG is designed for In Vitro Diagnostic Use Only for the quantitative measurement of sex hormone binding globulin (SHBG) in human serum or Na heparinized plasma on Tosoh AIA System Analyzers. The ST AIA-PACK SHBG assay is intended for use as an aid in the diagnosis of androgen disorders.",
        "regulation_section": "21 CFR 862.1680",
        "product_code": "CDZ",
        "comparison_with_predicate": "For the quantitative measurement of sex hormone binding globulin (SHBG) in human serum and plasma for use as an aid in the diagnosis of androgen disorders."
    },
    "K150815.txt": {
        "applicant": "BD Biosciences",
        "conclusion": "The submitted information in this premarket notification is complete and supports a substantial equivalence decision.",
        "classification": "Class II (assay) Class II (controls)",
        "panel": "Hematology (81) Immunology (82)",
        "measurand": "Lymphocyte CD4 absolute count, CD4 percentage of lymphocytes, and hemoglobin concentration",
        "submission_number": "K150815",
        "intended_use": "BD FACSPresto\u2122 System is an automated multicolor fluorescent imaging cytometer and absorbance spectrometer to be used in conjunction with single use reagent cartridges in performing the direct cell enumeration and measurement of absorbance spectrums. For use with the BD FACSPresto CD4/Hb Cartridge and BD FACSPresto CD4/Hb Cartridge Kit in the direct quantification and enumeration of CD4 absolute count, CD4 of lymphocyte, and determination of hemoglobin concentration in normal and HIV positive patients in conjunction with other laboratory and clinical findings. For use in children, adolescents, and adults. For use with human whole blood from fingerstick and/or venous collections in K2 EDTA or K3 EDTA blood collection tubes. Not for point-of-care use. For in vitro diagnostic use.",
        "regulation_section": "21 CFR \u00a7864.5220, Automated Differential Cell Counter 21 CFR \u00a7864.8625, Hematology Quality Control Mixture",
        "product_code": "PMG, Automated multicolor fluorescent imaging cytometric analysis system OYE, System, Test, Flow cytometric reagents and accessories GKL Hemoglobin assay JPK, Analyte Controls, Hematology Quality Control",
        "comparison_with_predicate": "BD FACSPresto System is an automated multicolor fluorescent imaging cytometer and absorbance spectrometer to be used in conjunction with single use reagent cartridges in performing the direct cell enumeration and /or measurement of absorbance spectrums. For use with any flow cytometer equipped with a 488 nm laser and capable of detection in the ranges: 510\u2212545 nm, 562\u2212607 nm, and >650 nm. For use in erythrocyte-lysed whole peripheral blood. For use with or without isotype control. To characterize and monitor some forms of autoimmune disease. To characterize and monitor some forms of immunodeficiency disease, such as in HIV-infected individuals."
    },
    "K152386.txt": {
        "applicant": "Luminex Molecular Diagnostics, Inc.",
        "conclusion": "NxTAG Respiratory Pathogen Panel is substantially equivalent to the BioFire Diagnostics, LLC FilmArray Respiratory Panel.",
        "classification": "Class II",
        "panel": "Microbiology (83)",
        "measurand": "Influenza A RNA: Flu A Matrix (M) gene, Flu A H1 (HA) gene, Flu A H3 (HA) gene Influenza B RNA: Flu B Matrix (M) gene RSV A and RSV B: RNA L Polymerase gene Coronaviruses 229E, OC43 and NL63 RNA: Nucleocapsidprotein (N) gene Coronavirus HKU1: open reading frame 1 ab Human Metapneumovirus RNA: Phosphoprotein (P) gene Rhinovirus/Enterovirus RNA: 5\u2019-UTR Adenovirus DNA: Hexon gene Parainfluenza virus RNA: Parainfluenza 1 HN gene, Parainfluenza 2 and 3 NP gene, Parainfluenza virus 4 phosphoprotein (P) gene Human Bocavirus DNA: NP1 gene Chlamydophila pneumoniae DNA: rpoB gene Mycoplasma pneumoniae DNA: P1 gene",
        "submission_number": "K152386",
        "intended_use": "NxTAG Respiratory Pathogen Panel is a qualitative test intended for use on the Luminex MAGPIX Instrument for the simultaneous detection and identification of nucleic acids from multiple respiratory viruses and bacteria extracted from nasopharyngeal swabs collected from individuals with clinical signs and symptoms of a respiratory tract infection. The organism types and subtypes detected by the test are Influenza A, Influenza A H1, Influenza A H3, Influenza B, Respiratory Syncytial Virus A, Respiratory Syncytial Virus B, Coronavirus 229E, Coronavirus OC43, Coronavirus NL63, Coronavirus HKU1, Human Metapneumovirus, Rhinovirus/Enterovirus, Adenovirus, Parainfluenza virus 1, Parainfluenza virus 2, Parainfluenza virus 3, Parainfluenza virus 4, Human Bocavirus, Chlamydophila pneumoniae, and Mycoplasma pneumoniae. The test is indicated as an aid in the detection and identification of viral and bacterial agents causing respiratory tract infections in symptomatic adult and pediatric patients, who are either hospitalized, admitted to emergency departments or who are outpatients with suspected respiratory tract infection.",
        "regulation_section": "21 CFR 866.3980, Respiratory viral panel multiplex nucleic acid assay",
        "product_code": "OCC, OOI, OEM, OOU, OEP, OTG, OZY, OZX",
        "comparison_with_predicate": "NxTAG RPP is a qualitative test intended for use on the Luminex MAGPIX Instrument for the simultaneous detection and identification of nucleic acids from multiple respiratory viruses and bacteria extracted from nasopharyngeal swabs collected from individuals with clinical signs and symptoms of a respiratory tract infection. The organism types and subtypes detected by the test are Influenza A, Influenza A H1, Influenza A H3, Influenza B, Respiratory Syncytial Virus A, Respiratory Syncytial Virus B, Coronavirus 229E, Coronavirus OC43, Coronavirus NL63, Coronavirus HKU1, Human Metapneumovirus, Rhinovirus/Enterovirus, Adenovirus, Parainfluenza virus 1, Parainfluenza virus 2, Parainfluenza virus 3, Parainfluenza virus 4, Human Bocavirus, Chlamydophila pneumoniae, and Mycoplasma pneumoniae. The test is indicated as an aid in the detection and identification of viral and bacterial agents causing respiratory tract infections in symptomatic adult and pediatric patients, who are either hospitalized, admitted to emergency departments or who are outpatients with suspected respiratory tract infection."
    },
    "K170293.txt": {
        "applicant": "Siemens Healthcare Diagnostics, Inc.",
        "conclusion": "The submitted information in this premarket notification is complete and supports a substantial equivalence decision.",
        "classification": "Class II",
        "panel": "91 - Toxicology",
        "measurand": "Benzoylecgonine",
        "submission_number": "k170293",
        "intended_use": "The Emit II Plus Cocaine Metabolite Assay is a homogeneous enzyme immunoassay with a 150 ng/mL or 300 ng/mL cutoff. The assay is intended for use in the qualitative and semiquantitative analyses of benzoylecgonine (cocaine metabolite) in human urine.",
        "regulation_section": "21 CFR 862.3250",
        "product_code": "DIO \u2013 Cocaine and cocaine metabolic test system",
        "comparison_with_predicate": "Similarities: Intended Use, Measurant, Type of Test, Antibody, Reagent Form, Reagent Composition, Cutoff/controls, Sample Matrix. Difference: Instrument - Beckman Coulter DxC 700 AU Clinical Chemistry Analyzer vs SYVA 30R Biochemical System."
    },
    "K182922.txt": {
        "applicant": "Liofilchem s.r.l.",
        "conclusion": "The submitted information in this premarket notification is complete and supports a substantial equivalence decision.",
        "classification": "II",
        "panel": "83 \u2013 Microbiology",
        "measurand": "Omadacycline 0.002-32 \u03bcg/mL",
        "submission_number": "K182922",
        "intended_use": "The Liofilchem MTS (MIC Test Strip) Omadacycline 0.002-32 \u03bcg/mL is a quantitative method intended for the in vitro determination of antimicrobial susceptibility of bacteria.",
        "regulation_section": "866.1640 Antimicrobial Susceptibility Test Powder",
        "product_code": "JWY - Manual Antimicrobial Susceptibility Test Systems",
        "comparison_with_predicate": "Liofilchem MTS, vancomycin (K153687)"
    },
    "K150281.txt": {
        "applicant": "Nova Biomedical Corporation",
        "conclusion": "The submitted information in this premarket notification is complete and supports a substantial equivalence decision.",
        "classification": "Class II",
        "panel": "Clinical Chemistry (75)",
        "measurand": "Capillary whole blood glucose, venous, arterial, neonate arterial, and neonate heelstick samples.",
        "submission_number": "k150281",
        "intended_use": "The StatStrip Glucose Hospital Meter System is intended for point-of-care, in vitro diagnostic, multiple-patient use for the quantitative determination of glucose in capillary finger stick, venous whole blood, arterial whole blood, neonate arterial whole blood and neonate heel stick specimens.",
        "regulation_section": "21 CFR 862.1345, Glucose test system",
        "product_code": "CGA, Glucose Oxidase, Glucose",
        "comparison_with_predicate": "Similarities and Differences Item Predicate Device (k132121) Candidate Device (k150281) Brand Name Nova StatStrip Glucose Hospital Meter System Same Indications for Use/Intended Use For the quantitative determination of glucose in capillary finger stick, venous whole blood, arterial whole blood, neonate arterial whole blood and neonate heel stick specimens. Also for the quantitative determination of glucose in venous whole blood, arterial whole blood, neonatal heel stick, and neonatal arterial whole blood throughout all hospital and all professional healthcare settings. Same Enzyme Glucose Oxidase Same Test Principle Electro-chemical biosensor Same Sample type Capillary finger stick, venous and arterial whole blood, neonatal arterial whole blood and neonatal heelstick. Venous and arterial whole blood, neonatal arterial whole blood, and neonatal heelstick in all hospital and all professional healthcare settings. Measuring range 10-600 mg/dL Same Measuring time 6 sec Same Sample volume 1.2 \u00b5L Same Control solutions 3 liquid levels Same Linearity solutions 5 liquid levels Same Data Storage 1000 Patient Test 200 QC Tests 4000 Operators Same Wi-Fi network connectivity None Yes Meter dimension and weight 153 mm (6.0 in) x 82.5 mm (3.25 in) x 46 mm (1.8 in) 266 grams (0.6 lb) 146 mm (5.8 in) x 79 mm (3.1 in) x 30 mm (1.18 in) 220 grams (0.49 lb) Strip ejector button None Yes Docking/Charging Station single station only single, dual and quad stations"
    },
    "K161831.txt": {
        "applicant": "Immunodiagnostic Systems Limited",
        "conclusion": "The submitted information in this premarket notification is complete and supports a substantial equivalence decision.",
        "classification": "Class II",
        "panel": "Clinical Chemistry (75)",
        "measurand": "Total 25-hydroxyvitamin D",
        "submission_number": "k161831",
        "intended_use": "The IDS-iSYS 25 VitDS Assay is intended for the quantitative determination of total 25-hydroxyvitamin D [(25(OH)D] in human serum or plasma on the IDS-iSYS Multi-Discipline Automated System. Results are to be used in conjunction with other clinical and laboratory data to assist the clinician in the assessment of vitamin D sufficiency in an adult population.",
        "regulation_section": "21 CFR 862.1825, Vitamin D Test System",
        "product_code": "MRG, Vitamin D Test System",
        "comparison_with_predicate": "The candidate device (IDS-iSYS 25 VitDS assay) is a modification of the predicate device (IDS-iSYS 25-Hydroxy Vitamin DS assay (k140554)) and the main differences are the source of antibody pools and the calibrator matrix used."
    },
    "K172287.txt": {
        "applicant": "QIAGEN",
        "conclusion": "The submitted information in this premarket notification is complete and supports a substantial equivalence decision.",
        "classification": "Class II",
        "panel": "88 \u2013 Pathology",
        "measurand": "Janus Tyrosine Kinase 2 (JAK2) gene mutation G1849T (V617F)",
        "submission_number": "K172287",
        "intended_use": "The ipsogen JAK2 RGQ PCR Kit is a qualitative in vitro diagnostic test for the detection of the JAK2 V617F/G1849T allele in genomic DNA extracted from EDTA whole blood. The ipsogen JAK2 RGQ PCR Kit is a real time PCR test performed on the QIAGEN Rotor-Gene Q MDx instrument. The test is intended for use as an adjunct to evaluation of suspected myeloproliferative neoplasms, in conjunction with other clinicopathological factors.",
        "regulation_section": "21 CFR 866.6070",
        "product_code": "PSU",
        "comparison_with_predicate": "The test is intended for use as an adjunct to evaluation of suspected Myeloproliferative Neoplasms, in conjunction with other clinicopathological factors. This test does not detect less common JAK2 mutations associated with Myeloproliferative Neoplasms including mutations in exon 12 and is not intended for stand-alone diagnosis of Myeloproliferative Neoplasms."
    },
    "K170974.txt": {
        "applicant": "BD Biosciences",
        "conclusion": "The submitted information in this premarket notification is complete and supports a substantial equivalence decision.",
        "classification": "Class II",
        "panel": "Hematology (81)",
        "measurand": "Lymphocyte subsets",
        "submission_number": "K170974",
        "intended_use": "The BD FACSLyric\u2122 flow cytometer is intended for use as an in vitro diagnostic device for immunophenotyping using up to six fluorescence detection channels and two light scatter channels using a blue (488-nm) and a red (640-nm) laser. It is intended for use with in vitro diagnostic (IVD) assays and software that are indicated for use with the instrument.",
        "regulation_section": "21 CFR \u00a7864.5220, Automated Differential Cell Counter",
        "product_code": "OYE, flow cytometric reagents and accessories",
        "comparison_with_predicate": "The BD FACSLyric\u2122 flow cytometer is intended for use as an in vitro diagnostic device for immunophenotyping using up to six fluorescence detection channels and two light scatter channels using a blue (488-nm) and a red (640-nm) laser. It is intended for use with in vitro diagnostic (IVD) assays and software that are indicated for use with the instrument. The BD FACSCanto\u2122 II flow cytometers (4-2-2 and 5-3 configurations) function as part of a system with dedicated clinical software intended for use with cleared or approved in vitro diagnostic (IVD) assays that are indicated for use with the instrument for the identification and enumeration of human cell subsets. Only six detection channels using a blue (488 nm) and a red (633 nm) laser have been cleared for in vitro diagnostic use."
    },
    "K151917.txt": {
        "applicant": "Luminex Corporation",
        "conclusion": "The submitted information in this premarket notification is complete and supports a substantial equivalence decision.",
        "classification": "Class II (special controls)",
        "panel": "Chemistry (75)",
        "measurand": "nucleic acids",
        "submission_number": "k151917",
        "intended_use": "The Luminex ARIES\u00ae System is an in vitro diagnostic (IVD) platform that performs nucleic acid based tests in clinical laboratories. The Luminex ARIES\u00ae System is capable of automated extraction and purification of nucleic acids from multiple sample types as well as the automated amplification and detection of target nucleic acid sequences by fluorescence-based PCR.",
        "regulation_section": "21 CFR 862.2570 Instrumentation for clinical multiplex test systems",
        "product_code": "OOI \u2013 Real-time nucleic acid amplification",
        "comparison_with_predicate": "Similarities: Intended Use, Sample Preparation Method, Assay Format, Interpretation of Test Results. Differences: Fluidics, Assay Cartridge, Fluorescence Channels, Software."
    },
    "K162526.txt": {
        "applicant": "Roche Diagnostics",
        "conclusion": "The submitted information in this premarket notification is complete and supports a substantial equivalence decision.",
        "classification": "Class II",
        "panel": "Clinical Chemistry (75)",
        "measurand": "Creatine kinase MB subunit",
        "submission_number": "k162526",
        "intended_use": "The Creatine Kinase-MB assay is an in vitro test for the quantitative determination of the catalytic activity of creatine kinase MB subunit (CK-MB) in human serum and plasma on Roche/Hitachi cobas c systems. Measurements of creatine phosphokinase and its isoenzymes are used in the diagnosis and treatment of myocardial infarction and muscle diseases such as progressive, Duchenne-type muscular dystrophy.",
        "regulation_section": "21 CFR 862.1215, Creatine phosphokinase/creatine kinase or isoenzymes test system",
        "product_code": "JHW, U.V. Method, Cpk Isoenzymes",
        "comparison_with_predicate": "Similarities: Intended Use - In vitro quantitative determination of creatine kinase MB isoenzyme in human serum and plasma. Sample Type/Matrix - Serum and plasma. Traceability/Standardization - Traceable to the IFCC CK method. Differences: Reagent Composition - R1 Imidazole buffer (different HK (yeast) and G6PDH concentrations) and R2 CAPSO buffer. Additives have been added to both buffers. Reagent On-Board Stability - 8 weeks on-board in use and refrigerated on the analyzer. Measuring Range - 10 \u2013 2000 U/L (0.08-33.4 \u03bckat/L). Detection Limits - Limit of Blank = 3 U/L (0.05 \u03bckat/L), Limit of Detection = 3 U/L (0.05 \u03bckat/L), Limit of Quantitation = 10 U/L (0.08 \u03bckat/L)."
    },
    "K193393.txt": {
        "applicant": "Leica Biosystems Newcastle Ltd.",
        "conclusion": "The submitted information in this premarket notification is complete and supports a substantial equivalence decision.",
        "classification": "Class II",
        "panel": "Immunohistochemistry Reagents and Kits",
        "measurand": "Human Progesterone Receptor in formalin-fixed, paraffin embedded breast cancer tissue.",
        "submission_number": "K193393",
        "intended_use": "For in vitro diagnostic use. BOND Ready-to-Use Primary Antibody Progesterone Receptor (16) is a monoclonal antibody intended to be used for the qualitative identification by light microscopy of human progesterone receptor in formalin-fixed, paraffin-embedded tissue by immunohistochemical staining using the automated BOND-MAX or BOND-III systems.",
        "regulation_section": "21 CFR 864.1860",
        "product_code": "MXZ",
        "comparison_with_predicate": "Device & Predicate Device(s): K193393 K171753 Device Trade Name BOND Ready-to-Use Primary Antibody Progesterone Receptor (16), Novocastra Liquid Mouse Monoclonal Antibody Progesterone Receptor Clone 16 (Concentrated Liquid Antibody Format) BOND Ready-to-Use Primary Antibody Progesterone Receptor (16), Novocastra Liquid Mouse Monoclonal Antibody Progesterone Receptor Clone 16 General Device Characteristic Similarities Intended Use/Indications for Use Qualitative identification of human Progesterone Receptor in breast cancer patients Same Antibody Type Mouse monoclonal Same Isotype IgG1 Same PR Clone 16 Same Immunogen A prokaryotic recombinant protein corresponding to the N-terminal region of the A form of the human progesterone receptor Same Storage 2-80 C Same Technology Immunohistochemistry Same Tissue Type Formalin-fixed paraffin-embedded breast cancer tissue Same Staining Pattern Nuclear Same Staining Protocol IHC Protocol F Same General Device Characteristic Differences Staining Instrument BOND-III & BOND-MAX BOND-MAX RTU Antibody Progesterone Receptor (16) Configuration 7 mL & 30 mL 7 mL"
    }
}